JPH0555509B2 - - Google Patents
Info
- Publication number
- JPH0555509B2 JPH0555509B2 JP8848464A JP4846488A JPH0555509B2 JP H0555509 B2 JPH0555509 B2 JP H0555509B2 JP 8848464 A JP8848464 A JP 8848464A JP 4846488 A JP4846488 A JP 4846488A JP H0555509 B2 JPH0555509 B2 JP H0555509B2
- Authority
- JP
- Japan
- Prior art keywords
- benzothiepino
- pyridazin
- tetrahydro
- chlorophenyl
- dihydro
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- -1 hydroxy, amino Chemical group 0.000 claims description 45
- 125000000217 alkyl group Chemical group 0.000 claims description 31
- 125000003118 aryl group Chemical group 0.000 claims description 13
- 229910052736 halogen Inorganic materials 0.000 claims description 7
- 150000002367 halogens Chemical class 0.000 claims description 7
- 125000005236 alkanoylamino group Chemical group 0.000 claims description 6
- 125000003545 alkoxy group Chemical group 0.000 claims description 6
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 6
- 125000001072 heteroaryl group Chemical group 0.000 claims description 6
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 6
- 125000001424 substituent group Chemical group 0.000 claims description 6
- 229910052739 hydrogen Inorganic materials 0.000 claims description 5
- 239000001257 hydrogen Substances 0.000 claims description 5
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 5
- 125000004435 hydrogen atom Chemical class [H]* 0.000 claims description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 61
- 150000001875 compounds Chemical class 0.000 description 61
- 238000002844 melting Methods 0.000 description 51
- 230000008018 melting Effects 0.000 description 51
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 34
- 238000000034 method Methods 0.000 description 25
- 238000006243 chemical reaction Methods 0.000 description 23
- AAILEWXSEQLMNI-UHFFFAOYSA-N 1h-pyridazin-6-one Chemical class OC1=CC=CN=N1 AAILEWXSEQLMNI-UHFFFAOYSA-N 0.000 description 21
- 239000002904 solvent Substances 0.000 description 18
- 238000012360 testing method Methods 0.000 description 18
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 18
- 230000000694 effects Effects 0.000 description 16
- 238000000354 decomposition reaction Methods 0.000 description 14
- 239000000203 mixture Substances 0.000 description 14
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 12
- 239000013078 crystal Substances 0.000 description 12
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 10
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 9
- 238000001914 filtration Methods 0.000 description 9
- 238000003756 stirring Methods 0.000 description 9
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 8
- 241001465754 Metazoa Species 0.000 description 8
- 241000699670 Mus sp. Species 0.000 description 8
- 230000000949 anxiolytic effect Effects 0.000 description 8
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 8
- 229910052794 bromium Inorganic materials 0.000 description 8
- 238000010992 reflux Methods 0.000 description 8
- 210000000265 leukocyte Anatomy 0.000 description 7
- FQHCPFMTXFJZJS-UHFFFAOYSA-N (4-methoxyphenyl)hydrazine;hydrochloride Chemical compound Cl.COC1=CC=C(NN)C=C1 FQHCPFMTXFJZJS-UHFFFAOYSA-N 0.000 description 6
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 6
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 6
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 6
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- 239000002249 anxiolytic agent Substances 0.000 description 6
- GLFHMYMOGBMFKJ-UHFFFAOYSA-N 10-chloro-2-(4-chlorophenyl)-5,6-dihydro-[1]benzothiepino[5,4-c]pyridazin-3-one Chemical compound C1=CC(Cl)=CC=C1N1C(=O)C=C(CCSC=2C3=CC(Cl)=CC=2)C3=N1 GLFHMYMOGBMFKJ-UHFFFAOYSA-N 0.000 description 5
- 241000700159 Rattus Species 0.000 description 5
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 5
- 238000004440 column chromatography Methods 0.000 description 5
- AAOVKJBEBIDNHE-UHFFFAOYSA-N diazepam Chemical compound N=1CC(=O)N(C)C2=CC=C(Cl)C=C2C=1C1=CC=CC=C1 AAOVKJBEBIDNHE-UHFFFAOYSA-N 0.000 description 5
- 229960003529 diazepam Drugs 0.000 description 5
- INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 5
- 235000013336 milk Nutrition 0.000 description 5
- 239000008267 milk Substances 0.000 description 5
- 210000004080 milk Anatomy 0.000 description 5
- 230000000144 pharmacologic effect Effects 0.000 description 5
- LEJAYRGELPEHFV-UHFFFAOYSA-N 10-chloro-2-(4-chlorophenyl)-4,4a,5,6-tetrahydro-[1]benzothiepino[5,4-c]pyridazin-3-one Chemical compound C1=CC(Cl)=CC=C1N1C(=O)CC(CCSC=2C3=CC(Cl)=CC=2)C3=N1 LEJAYRGELPEHFV-UHFFFAOYSA-N 0.000 description 4
- IIDYJQBIULBPTJ-UHFFFAOYSA-N 2-(4-bromophenyl)-4,4a,5,6-tetrahydro-[1]benzothiepino[5,4-c]pyridazin-3-one Chemical compound C1=CC(Br)=CC=C1N1C(=O)CC(CCSC=2C3=CC=CC=2)C3=N1 IIDYJQBIULBPTJ-UHFFFAOYSA-N 0.000 description 4
- 102000004300 GABA-A Receptors Human genes 0.000 description 4
- 108090000839 GABA-A Receptors Proteins 0.000 description 4
- 206010057249 Phagocytosis Diseases 0.000 description 4
- 230000009471 action Effects 0.000 description 4
- 150000001557 benzodiazepines Chemical class 0.000 description 4
- 230000027455 binding Effects 0.000 description 4
- 239000012043 crude product Substances 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 238000010438 heat treatment Methods 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 230000008782 phagocytosis Effects 0.000 description 4
- HKOOXMFOFWEVGF-UHFFFAOYSA-N phenylhydrazine Chemical compound NNC1=CC=CC=C1 HKOOXMFOFWEVGF-UHFFFAOYSA-N 0.000 description 4
- 229940067157 phenylhydrazine Drugs 0.000 description 4
- 238000003825 pressing Methods 0.000 description 4
- 230000028527 righting reflex Effects 0.000 description 4
- 238000010898 silica gel chromatography Methods 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 239000000725 suspension Substances 0.000 description 4
- 238000005406 washing Methods 0.000 description 4
- QKMNPUHPWJFRFL-UHFFFAOYSA-N 10-fluoro-2-(4-fluorophenyl)-5,6-dihydro-[1]benzothiepino[5,4-c]pyridazin-3-one Chemical compound C1=CC(F)=CC=C1N1C(=O)C=C(CCSC=2C3=CC(F)=CC=2)C3=N1 QKMNPUHPWJFRFL-UHFFFAOYSA-N 0.000 description 3
- DSKPZHRMHYDUHZ-UHFFFAOYSA-N 2-(4-chlorophenyl)-4,4a,5,6-tetrahydro-[1]benzothiepino[5,4-c]pyridazin-3-one Chemical compound C1=CC(Cl)=CC=C1N1C(=O)CC(CCSC=2C3=CC=CC=2)C3=N1 DSKPZHRMHYDUHZ-UHFFFAOYSA-N 0.000 description 3
- YIEYSFIVIUQNBF-UHFFFAOYSA-N 2-(4-chlorophenyl)-5,6-dihydro-[1]benzothiepino[5,4-c]pyridazin-3-one Chemical compound C1=CC(Cl)=CC=C1N1C(=O)C=C(CCSC=2C3=CC=CC=2)C3=N1 YIEYSFIVIUQNBF-UHFFFAOYSA-N 0.000 description 3
- XXNOGQJZAOXWAQ-UHFFFAOYSA-N 4-chlorophenylhydrazine Chemical compound NNC1=CC=C(Cl)C=C1 XXNOGQJZAOXWAQ-UHFFFAOYSA-N 0.000 description 3
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- 208000019901 Anxiety disease Diseases 0.000 description 3
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
- 125000003277 amino group Chemical group 0.000 description 3
- 229940005530 anxiolytics Drugs 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- 238000001035 drying Methods 0.000 description 3
- 210000002540 macrophage Anatomy 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 150000003839 salts Chemical class 0.000 description 3
- OQTSXIJQJPCVIU-UHFFFAOYSA-N 2-(3,4-dichlorophenyl)-10-fluoro-5,6-dihydro-[1]benzothiepino[5,4-c]pyridazin-3-one Chemical compound N1=C2C3=CC(F)=CC=C3SCCC2=CC(=O)N1C1=CC=C(Cl)C(Cl)=C1 OQTSXIJQJPCVIU-UHFFFAOYSA-N 0.000 description 2
- PTHZTNTXODWBHO-UHFFFAOYSA-N 2-(4-bromophenyl)-7-oxo-5,6-dihydro-[1]benzothiepino[5,4-c]pyridazin-3-one Chemical compound C1=CC(Br)=CC=C1N1C(=O)C=C(CCS(=O)C=2C3=CC=CC=2)C3=N1 PTHZTNTXODWBHO-UHFFFAOYSA-N 0.000 description 2
- CDXGDOAOYZJBAQ-UHFFFAOYSA-N 2-(4-chlorophenyl)-10-fluoro-5,6-dihydro-[1]benzothiepino[5,4-c]pyridazin-3-one Chemical compound N1=C2C3=CC(F)=CC=C3SCCC2=CC(=O)N1C1=CC=C(Cl)C=C1 CDXGDOAOYZJBAQ-UHFFFAOYSA-N 0.000 description 2
- NGTOQMBNKLHRJA-UHFFFAOYSA-N 2-[(4-chlorophenyl)methyl]-5,6-dihydro-[1]benzothiepino[5,4-c]pyridazin-3-one Chemical compound C1=CC(Cl)=CC=C1CN1C(=O)C=C(CCSC=2C3=CC=CC=2)C3=N1 NGTOQMBNKLHRJA-UHFFFAOYSA-N 0.000 description 2
- HYICCTJUXYNMNK-UHFFFAOYSA-N 4,4a,5,6-tetrahydro-2h-[1]benzothiepino[5,4-c]pyridazin-3-one Chemical compound C1CSC2=CC=CC=C2C2=NNC(=O)CC21 HYICCTJUXYNMNK-UHFFFAOYSA-N 0.000 description 2
- VSDILCSZFNGZRF-UHFFFAOYSA-N 8-chloro-2-(4-chlorophenyl)-7-oxo-5,6-dihydro-[1]benzothiepino[5,4-c]pyridazin-3-one Chemical compound C1=CC(Cl)=CC=C1N1C(=O)C=C(CCS(=O)C=2C3=CC=CC=2Cl)C3=N1 VSDILCSZFNGZRF-UHFFFAOYSA-N 0.000 description 2
- 206010002091 Anaesthesia Diseases 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 229920002261 Corn starch Polymers 0.000 description 2
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 2
- 241000588724 Escherichia coli Species 0.000 description 2
- OAKJQQAXSVQMHS-UHFFFAOYSA-N Hydrazine Chemical compound NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 206010021118 Hypotonia Diseases 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 2
- KFSLWBXXFJQRDL-UHFFFAOYSA-N Peracetic acid Chemical compound CC(=O)OO KFSLWBXXFJQRDL-UHFFFAOYSA-N 0.000 description 2
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 2
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 2
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- WQDUMFSSJAZKTM-UHFFFAOYSA-N Sodium methoxide Chemical compound [Na+].[O-]C WQDUMFSSJAZKTM-UHFFFAOYSA-N 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 208000007502 anemia Diseases 0.000 description 2
- 230000003276 anti-hypertensive effect Effects 0.000 description 2
- 230000036506 anxiety Effects 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 125000004429 atom Chemical group 0.000 description 2
- 229940049706 benzodiazepine Drugs 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 239000007795 chemical reaction product Substances 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 229910052801 chlorine Inorganic materials 0.000 description 2
- 239000000460 chlorine Substances 0.000 description 2
- WORJEOGGNQDSOE-UHFFFAOYSA-N chloroform;methanol Chemical compound OC.ClC(Cl)Cl WORJEOGGNQDSOE-UHFFFAOYSA-N 0.000 description 2
- 239000008120 corn starch Substances 0.000 description 2
- 229960004397 cyclophosphamide Drugs 0.000 description 2
- IYGYMKDQCDOMRE-UHFFFAOYSA-N d-Bicucullin Natural products CN1CCC2=CC=3OCOC=3C=C2C1C1OC(=O)C2=C1C=CC1=C2OCO1 IYGYMKDQCDOMRE-UHFFFAOYSA-N 0.000 description 2
- 230000007123 defense Effects 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 238000010828 elution Methods 0.000 description 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- UYXAWHWODHRRMR-UHFFFAOYSA-N hexobarbital Chemical compound O=C1N(C)C(=O)NC(=O)C1(C)C1=CCCCC1 UYXAWHWODHRRMR-UHFFFAOYSA-N 0.000 description 2
- 229960002456 hexobarbital Drugs 0.000 description 2
- 150000002429 hydrazines Chemical class 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 2
- 230000036640 muscle relaxation Effects 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- SCVFZCLFOSHCOH-UHFFFAOYSA-M potassium acetate Chemical compound [K+].CC([O-])=O SCVFZCLFOSHCOH-UHFFFAOYSA-M 0.000 description 2
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- 238000001953 recrystallisation Methods 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 239000001632 sodium acetate Substances 0.000 description 2
- 235000017281 sodium acetate Nutrition 0.000 description 2
- 239000012312 sodium hydride Substances 0.000 description 2
- 229910000104 sodium hydride Inorganic materials 0.000 description 2
- FRAKPAVZKUGWSR-UHFFFAOYSA-M sodium;bromite;trihydrate Chemical compound O.O.O.[Na+].[O-]Br=O FRAKPAVZKUGWSR-UHFFFAOYSA-M 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 210000003568 synaptosome Anatomy 0.000 description 2
- 239000000454 talc Substances 0.000 description 2
- 229910052623 talc Inorganic materials 0.000 description 2
- 238000012549 training Methods 0.000 description 2
- CRRIAWUJYMLJOE-UHFFFAOYSA-N (3-chlorophenyl)hydrazine;hydron;chloride Chemical compound Cl.NNC1=CC=CC(Cl)=C1 CRRIAWUJYMLJOE-UHFFFAOYSA-N 0.000 description 1
- RGGOWBBBHWTTRE-UHFFFAOYSA-N (4-bromophenyl)hydrazine;hydron;chloride Chemical compound Cl.NNC1=CC=C(Br)C=C1 RGGOWBBBHWTTRE-UHFFFAOYSA-N 0.000 description 1
- YQVZREHUWCCHHX-UHFFFAOYSA-N (4-chlorophenyl)hydrazine;hydron;chloride Chemical compound Cl.NNC1=CC=C(Cl)C=C1 YQVZREHUWCCHHX-UHFFFAOYSA-N 0.000 description 1
- HMHWNJGOHUYVMD-UHFFFAOYSA-N (4-methylanilino)azanium;chloride Chemical compound Cl.CC1=CC=C(NN)C=C1 HMHWNJGOHUYVMD-UHFFFAOYSA-N 0.000 description 1
- MPPPKRYCTPRNTB-UHFFFAOYSA-N 1-bromobutane Chemical compound CCCCBr MPPPKRYCTPRNTB-UHFFFAOYSA-N 0.000 description 1
- JQZAEUFPPSRDOP-UHFFFAOYSA-N 1-chloro-4-(chloromethyl)benzene Chemical compound ClCC1=CC=C(Cl)C=C1 JQZAEUFPPSRDOP-UHFFFAOYSA-N 0.000 description 1
- YZQAOIUQEJUTCP-UHFFFAOYSA-N 10-chloro-2-(4-chlorophenyl)-7-oxo-5,6-dihydro-[1]benzothiepino[5,4-c]pyridazin-3-one Chemical compound C1=CC(Cl)=CC=C1N1C(=O)C=C(CCS(=O)C=2C3=CC(Cl)=CC=2)C3=N1 YZQAOIUQEJUTCP-UHFFFAOYSA-N 0.000 description 1
- QTUADMKLXGUNBO-UHFFFAOYSA-N 10-fluoro-2-(4-fluorophenyl)-7-oxo-5,6-dihydro-[1]benzothiepino[5,4-c]pyridazin-3-one Chemical compound C1=CC(F)=CC=C1N1C(=O)C=C(CCS(=O)C=2C3=CC(F)=CC=2)C3=N1 QTUADMKLXGUNBO-UHFFFAOYSA-N 0.000 description 1
- IILBZRVUJYTNNV-UHFFFAOYSA-N 10-fluoro-7-oxo-2-[3-(trifluoromethyl)phenyl]-5,6-dihydro-[1]benzothiepino[5,4-c]pyridazin-3-one Chemical compound C=1C(F)=CC=C(S(CCC2=CC3=O)=O)C=1C2=NN3C1=CC=CC(C(F)(F)F)=C1 IILBZRVUJYTNNV-UHFFFAOYSA-N 0.000 description 1
- SVUOLADPCWQTTE-UHFFFAOYSA-N 1h-1,2-benzodiazepine Chemical compound N1N=CC=CC2=CC=CC=C12 SVUOLADPCWQTTE-UHFFFAOYSA-N 0.000 description 1
- AYJPYHRSFOISQA-UHFFFAOYSA-N 2-(2-chlorophenyl)-4,4a,5,6-tetrahydro-[1]benzothiepino[5,4-c]pyridazin-3-one Chemical compound ClC1=CC=CC=C1N1C(=O)CC(CCSC=2C3=CC=CC=2)C3=N1 AYJPYHRSFOISQA-UHFFFAOYSA-N 0.000 description 1
- NAVGADCTWBNCPQ-UHFFFAOYSA-N 2-(3-chlorophenyl)-4,4a,5,6-tetrahydro-[1]benzothiepino[5,4-c]pyridazin-3-one Chemical compound ClC1=CC=CC(N2C(CC3C(C4=CC=CC=C4SCC3)=N2)=O)=C1 NAVGADCTWBNCPQ-UHFFFAOYSA-N 0.000 description 1
- TYANXHYCUFWXFG-UHFFFAOYSA-N 2-(4-bromophenyl)-5,6-dihydro-[1]benzothiepino[5,4-c]pyridazin-3-one Chemical compound C1=CC(Br)=CC=C1N1C(=O)C=C(CCSC=2C3=CC=CC=2)C3=N1 TYANXHYCUFWXFG-UHFFFAOYSA-N 0.000 description 1
- WXVRWFDYIKCQMT-UHFFFAOYSA-N 2-(4-chlorophenyl)-10-fluoro-7-oxo-5,6-dihydro-[1]benzothiepino[5,4-c]pyridazin-3-one Chemical compound C=1C(F)=CC=C(S(CCC2=CC3=O)=O)C=1C2=NN3C1=CC=C(Cl)C=C1 WXVRWFDYIKCQMT-UHFFFAOYSA-N 0.000 description 1
- VIFGKSBYGOOBBG-UHFFFAOYSA-N 2-(4-chlorophenyl)-10-methyl-5,6-dihydro-[1]benzothiepino[5,4-c]pyridazin-3-one Chemical compound N1=C2C3=CC(C)=CC=C3SCCC2=CC(=O)N1C1=CC=C(Cl)C=C1 VIFGKSBYGOOBBG-UHFFFAOYSA-N 0.000 description 1
- SGMXTPJHXVMMHD-UHFFFAOYSA-N 2-(4-chlorophenyl)-10-methyl-7-oxo-5,6-dihydro-[1]benzothiepino[5,4-c]pyridazin-3-one Chemical compound C=1C(C)=CC=C(S(CCC2=CC3=O)=O)C=1C2=NN3C1=CC=C(Cl)C=C1 SGMXTPJHXVMMHD-UHFFFAOYSA-N 0.000 description 1
- VWUGYIRMRAOOAG-UHFFFAOYSA-N 2-(4-chlorophenyl)-7-oxo-4,4a,5,6-tetrahydro-[1]benzothiepino[5,4-c]pyridazin-3-one Chemical compound C1=CC(Cl)=CC=C1N1C(=O)CC(CCS(=O)C=2C3=CC=CC=2)C3=N1 VWUGYIRMRAOOAG-UHFFFAOYSA-N 0.000 description 1
- LPMSNKWSTXKGGR-UHFFFAOYSA-N 2-(4-fluorophenyl)-5,6-dihydro-[1]benzothiepino[5,4-c]pyridazin-3-one Chemical compound C1=CC(F)=CC=C1N1C(=O)C=C(CCSC=2C3=CC=CC=2)C3=N1 LPMSNKWSTXKGGR-UHFFFAOYSA-N 0.000 description 1
- LCPUGWKGOOTDCC-UHFFFAOYSA-N 2-(4-fluorophenyl)-7-oxo-5,6-dihydro-[1]benzothiepino[5,4-c]pyridazin-3-one Chemical compound C1=CC(F)=CC=C1N1C(=O)C=C(CCS(=O)C=2C3=CC=CC=2)C3=N1 LCPUGWKGOOTDCC-UHFFFAOYSA-N 0.000 description 1
- RQCPOXFVJUSNRL-UHFFFAOYSA-N 2-(4-methoxyphenyl)-4,4a,5,6-tetrahydro-[1]benzothiepino[5,4-c]pyridazin-3-one Chemical compound C1=CC(OC)=CC=C1N1C(=O)CC(CCSC=2C3=CC=CC=2)C3=N1 RQCPOXFVJUSNRL-UHFFFAOYSA-N 0.000 description 1
- KSUYUISXWPQBCX-UHFFFAOYSA-N 2-(5-oxo-3,4-dihydro-2h-1-benzothiepin-4-yl)acetic acid Chemical compound O=C1C(CC(=O)O)CCSC2=CC=CC=C21 KSUYUISXWPQBCX-UHFFFAOYSA-N 0.000 description 1
- KFGLLNVFBQRVQR-UHFFFAOYSA-N 2-(9-chloro-5-oxo-3,4-dihydro-2h-1-benzothiepin-4-yl)acetic acid Chemical compound O=C1C(CC(=O)O)CCSC2=C(Cl)C=CC=C21 KFGLLNVFBQRVQR-UHFFFAOYSA-N 0.000 description 1
- ADODRSVGNHNKAT-UHFFFAOYSA-N 2-Chlorophenylhydrazine hydrochloride Chemical compound Cl.NNC1=CC=CC=C1Cl ADODRSVGNHNKAT-UHFFFAOYSA-N 0.000 description 1
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- GQHVSNJPEAPQHK-UHFFFAOYSA-N 2-benzyl-5,6-dihydro-[1]benzothiepino[5,4-c]pyridazin-3-one Chemical compound O=C1C=C2CCSC3=CC=CC=C3C2=NN1CC1=CC=CC=C1 GQHVSNJPEAPQHK-UHFFFAOYSA-N 0.000 description 1
- JSGGKGHSDAQYJP-UHFFFAOYSA-N 2-butyl-5,6-dihydro-[1]benzothiepino[5,4-c]pyridazin-3-one Chemical compound C1CSC2=CC=CC=C2C2=NN(CCCC)C(=O)C=C12 JSGGKGHSDAQYJP-UHFFFAOYSA-N 0.000 description 1
- 125000004182 2-chlorophenyl group Chemical group [H]C1=C([H])C(Cl)=C(*)C([H])=C1[H] 0.000 description 1
- 125000002941 2-furyl group Chemical group O1C([*])=C([H])C([H])=C1[H] 0.000 description 1
- 125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 description 1
- 125000000175 2-thienyl group Chemical group S1C([*])=C([H])C([H])=C1[H] 0.000 description 1
- UPAXNLWDRLUQEA-UHFFFAOYSA-N 2h-[1]benzothiepino[5,4-c]pyridazin-3-one Chemical compound C1=CSC2=CC=CC=C2C2=NNC(=O)C=C21 UPAXNLWDRLUQEA-UHFFFAOYSA-N 0.000 description 1
- 125000005806 3,4,5-trimethoxybenzyl group Chemical group [H]C1=C(OC([H])([H])[H])C(OC([H])([H])[H])=C(OC([H])([H])[H])C([H])=C1C([H])([H])* 0.000 description 1
- 125000005809 3,4,5-trimethoxyphenyl group Chemical group [H]C1=C(OC([H])([H])[H])C(OC([H])([H])[H])=C(OC([H])([H])[H])C([H])=C1* 0.000 description 1
- 125000004189 3,4-dichlorophenyl group Chemical group [H]C1=C([H])C(Cl)=C(Cl)C([H])=C1* 0.000 description 1
- YNJSNEKCXVFDKW-UHFFFAOYSA-N 3-(5-amino-1h-indol-3-yl)-2-azaniumylpropanoate Chemical compound C1=C(N)C=C2C(CC(N)C(O)=O)=CNC2=C1 YNJSNEKCXVFDKW-UHFFFAOYSA-N 0.000 description 1
- NHQDETIJWKXCTC-UHFFFAOYSA-N 3-chloroperbenzoic acid Chemical compound OOC(=O)C1=CC=CC(Cl)=C1 NHQDETIJWKXCTC-UHFFFAOYSA-N 0.000 description 1
- 125000004179 3-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(Cl)=C1[H] 0.000 description 1
- 125000003682 3-furyl group Chemical group O1C([H])=C([*])C([H])=C1[H] 0.000 description 1
- 125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 description 1
- 125000001541 3-thienyl group Chemical group S1C([H])=C([*])C([H])=C1[H] 0.000 description 1
- 125000006283 4-chlorobenzyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1Cl)C([H])([H])* 0.000 description 1
- 125000004801 4-cyanophenyl group Chemical group [H]C1=C([H])C(C#N)=C([H])C([H])=C1* 0.000 description 1
- 125000001255 4-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1F 0.000 description 1
- 125000003143 4-hydroxybenzyl group Chemical group [H]C([*])([H])C1=C([H])C([H])=C(O[H])C([H])=C1[H] 0.000 description 1
- 125000004203 4-hydroxyphenyl group Chemical group [H]OC1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- 125000004217 4-methoxybenzyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1OC([H])([H])[H])C([H])([H])* 0.000 description 1
- 125000004172 4-methoxyphenyl group Chemical group [H]C1=C([H])C(OC([H])([H])[H])=C([H])C([H])=C1* 0.000 description 1
- 125000006181 4-methyl benzyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1C([H])([H])[H])C([H])([H])* 0.000 description 1
- 125000000339 4-pyridyl group Chemical group N1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 description 1
- KTPVHXCBYGDRPK-UHFFFAOYSA-N 5,6-dihydro-2h-[1]benzothiepino[5,4-c]pyridazin-3-one Chemical compound C1CSC2=CC=CC=C2C2=NNC(=O)C=C21 KTPVHXCBYGDRPK-UHFFFAOYSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- OBYBYNYGRYGJMO-UHFFFAOYSA-N 8-chloro-2-(4-chlorophenyl)-7,7-dioxo-5,6-dihydro-[1]benzothiepino[5,4-c]pyridazin-3-one Chemical compound C1=CC(Cl)=CC=C1N1C(=O)C=C(CCS(=O)(=O)C=2C3=CC=CC=2Cl)C3=N1 OBYBYNYGRYGJMO-UHFFFAOYSA-N 0.000 description 1
- 244000291564 Allium cepa Species 0.000 description 1
- 235000002732 Allium cepa var. cepa Nutrition 0.000 description 1
- 206010002383 Angina Pectoris Diseases 0.000 description 1
- 206010003445 Ascites Diseases 0.000 description 1
- 206010003840 Autonomic nervous system imbalance Diseases 0.000 description 1
- IYGYMKDQCDOMRE-QRWMCTBCSA-N Bicculine Chemical compound O([C@H]1C2C3=CC=4OCOC=4C=C3CCN2C)C(=O)C2=C1C=CC1=C2OCO1 IYGYMKDQCDOMRE-QRWMCTBCSA-N 0.000 description 1
- GAWIXWVDTYZWAW-UHFFFAOYSA-N C[CH]O Chemical group C[CH]O GAWIXWVDTYZWAW-UHFFFAOYSA-N 0.000 description 1
- 102000011632 Caseins Human genes 0.000 description 1
- 108010076119 Caseins Proteins 0.000 description 1
- 229940126062 Compound A Drugs 0.000 description 1
- 206010010904 Convulsion Diseases 0.000 description 1
- 206010013975 Dyspnoeas Diseases 0.000 description 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
- 238000007107 Gatterman reaction Methods 0.000 description 1
- 229920002527 Glycogen Polymers 0.000 description 1
- NLDMNSXOCDLTTB-UHFFFAOYSA-N Heterophylliin A Natural products O1C2COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC2C(OC(=O)C=2C=C(O)C(O)=C(O)C=2)C(O)C1OC(=O)C1=CC(O)=C(O)C(O)=C1 NLDMNSXOCDLTTB-UHFFFAOYSA-N 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 201000009053 Neurodermatitis Diseases 0.000 description 1
- 206010029333 Neurosis Diseases 0.000 description 1
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 1
- CWRVKFFCRWGWCS-UHFFFAOYSA-N Pentrazole Chemical compound C1CCCCC2=NN=NN21 CWRVKFFCRWGWCS-UHFFFAOYSA-N 0.000 description 1
- 208000012545 Psychophysiologic disease Diseases 0.000 description 1
- 238000000297 Sandmeyer reaction Methods 0.000 description 1
- 206010039897 Sedation Diseases 0.000 description 1
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 1
- 206010041349 Somnolence Diseases 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- FNKJECMULJNDHK-UHFFFAOYSA-N [1]benzothiepino[5,4-c]pyridazine Chemical class S1C=CC2=CC=NN=C2C2=CC=CC=C12 FNKJECMULJNDHK-UHFFFAOYSA-N 0.000 description 1
- 125000002252 acyl group Chemical group 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000001476 alcoholic effect Effects 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 230000003042 antagnostic effect Effects 0.000 description 1
- 230000002744 anti-aggregatory effect Effects 0.000 description 1
- 230000001253 anti-conflict Effects 0.000 description 1
- 230000001773 anti-convulsant effect Effects 0.000 description 1
- 230000002785 anti-thrombosis Effects 0.000 description 1
- 229940125713 antianxiety drug Drugs 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- KCXMKQUNVWSEMD-UHFFFAOYSA-N benzyl chloride Chemical compound ClCC1=CC=CC=C1 KCXMKQUNVWSEMD-UHFFFAOYSA-N 0.000 description 1
- 229940073608 benzyl chloride Drugs 0.000 description 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
- IYGYMKDQCDOMRE-ZWKOTPCHSA-N bicuculline Chemical compound O([C@H]1[C@@H]2C3=CC=4OCOC=4C=C3CCN2C)C(=O)C2=C1C=CC1=C2OCO1 IYGYMKDQCDOMRE-ZWKOTPCHSA-N 0.000 description 1
- AACMFFIUYXGCOC-UHFFFAOYSA-N bicuculline Natural products CN1CCc2cc3OCOc3cc2C1C4OCc5c6OCOc6ccc45 AACMFFIUYXGCOC-UHFFFAOYSA-N 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 239000012267 brine Substances 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 230000003177 cardiotonic effect Effects 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 210000003710 cerebral cortex Anatomy 0.000 description 1
- KXZJHVJKXJLBKO-UHFFFAOYSA-N chembl1408157 Chemical compound N=1C2=CC=CC=C2C(C(=O)O)=CC=1C1=CC=C(O)C=C1 KXZJHVJKXJLBKO-UHFFFAOYSA-N 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 229940125904 compound 1 Drugs 0.000 description 1
- JNGZXGGOCLZBFB-IVCQMTBJSA-N compound E Chemical compound N([C@@H](C)C(=O)N[C@@H]1C(N(C)C2=CC=CC=C2C(C=2C=CC=CC=2)=N1)=O)C(=O)CC1=CC(F)=CC(F)=C1 JNGZXGGOCLZBFB-IVCQMTBJSA-N 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 235000008504 concentrate Nutrition 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 239000003179 convulsant agent Substances 0.000 description 1
- 230000036461 convulsion Effects 0.000 description 1
- ZXIJMRYMVAMXQP-UHFFFAOYSA-N cycloheptene Chemical compound C1CCC=CCC1 ZXIJMRYMVAMXQP-UHFFFAOYSA-N 0.000 description 1
- UKJLNMAFNRKWGR-UHFFFAOYSA-N cyclohexatrienamine Chemical group NC1=CC=C=C[CH]1 UKJLNMAFNRKWGR-UHFFFAOYSA-N 0.000 description 1
- 230000001120 cytoprotective effect Effects 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 231100000517 death Toxicity 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 235000020805 dietary restrictions Nutrition 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 238000006073 displacement reaction Methods 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 230000001206 effect on leukocytes Effects 0.000 description 1
- 239000003480 eluent Substances 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- OAYLNYINCPYISS-UHFFFAOYSA-N ethyl acetate;hexane Chemical compound CCCCCC.CCOC(C)=O OAYLNYINCPYISS-UHFFFAOYSA-N 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 238000010575 fractional recrystallization Methods 0.000 description 1
- 239000003365 glass fiber Substances 0.000 description 1
- 229940096919 glycogen Drugs 0.000 description 1
- 125000003187 heptyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 150000004677 hydrates Chemical class 0.000 description 1
- 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 description 1
- 239000005457 ice water Substances 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 239000000411 inducer Substances 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
- 208000013433 lightheadedness Diseases 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 1
- 235000019341 magnesium sulphate Nutrition 0.000 description 1
- 125000005948 methanesulfonyloxy group Chemical group 0.000 description 1
- 239000012046 mixed solvent Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- WHQSYGRFZMUQGQ-UHFFFAOYSA-N n,n-dimethylformamide;hydrate Chemical compound O.CN(C)C=O WHQSYGRFZMUQGQ-UHFFFAOYSA-N 0.000 description 1
- 125000001624 naphthyl group Chemical group 0.000 description 1
- 125000004998 naphthylethyl group Chemical group C1(=CC=CC2=CC=CC=C12)CC* 0.000 description 1
- 125000004923 naphthylmethyl group Chemical group C1(=CC=CC2=CC=CC=C12)C* 0.000 description 1
- 125000001971 neopentyl group Chemical group [H]C([*])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 230000001272 neurogenic effect Effects 0.000 description 1
- 208000015238 neurotic disease Diseases 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 239000012454 non-polar solvent Substances 0.000 description 1
- 125000002347 octyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000007800 oxidant agent Substances 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 125000003854 p-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Cl 0.000 description 1
- 125000001037 p-tolyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)C([H])([H])[H] 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 229960005152 pentetrazol Drugs 0.000 description 1
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- 125000000286 phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000004344 phenylpropyl group Chemical group 0.000 description 1
- 231100000572 poisoning Toxicity 0.000 description 1
- 230000000607 poisoning effect Effects 0.000 description 1
- 239000002798 polar solvent Substances 0.000 description 1
- 229920006316 polyvinylpyrrolidine Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 235000011056 potassium acetate Nutrition 0.000 description 1
- 229910000027 potassium carbonate Inorganic materials 0.000 description 1
- 239000001103 potassium chloride Substances 0.000 description 1
- 235000011164 potassium chloride Nutrition 0.000 description 1
- NNFCIKHAZHQZJG-UHFFFAOYSA-N potassium cyanide Chemical compound [K+].N#[C-] NNFCIKHAZHQZJG-UHFFFAOYSA-N 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 1
- LVTJOONKWUXEFR-FZRMHRINSA-N protoneodioscin Natural products O(C[C@@H](CC[C@]1(O)[C@H](C)[C@@H]2[C@]3(C)[C@H]([C@H]4[C@@H]([C@]5(C)C(=CC4)C[C@@H](O[C@@H]4[C@H](O[C@H]6[C@@H](O)[C@@H](O)[C@@H](O)[C@H](C)O6)[C@@H](O)[C@H](O[C@H]6[C@@H](O)[C@@H](O)[C@@H](O)[C@H](C)O6)[C@H](CO)O4)CC5)CC3)C[C@@H]2O1)C)[C@H]1[C@H](O)[C@H](O)[C@H](O)[C@@H](CO)O1 LVTJOONKWUXEFR-FZRMHRINSA-N 0.000 description 1
- 150000004892 pyridazines Chemical class 0.000 description 1
- 125000004076 pyridyl group Chemical group 0.000 description 1
- 150000003856 quaternary ammonium compounds Chemical class 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 230000011514 reflex Effects 0.000 description 1
- 230000002787 reinforcement Effects 0.000 description 1
- 238000007363 ring formation reaction Methods 0.000 description 1
- 230000036280 sedation Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- ODZPKZBBUMBTMG-UHFFFAOYSA-N sodium amide Chemical compound [NH2-].[Na+] ODZPKZBBUMBTMG-UHFFFAOYSA-N 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 229940080237 sodium caseinate Drugs 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- QDRKDTQENPPHOJ-UHFFFAOYSA-N sodium ethoxide Chemical compound [Na+].CC[O-] QDRKDTQENPPHOJ-UHFFFAOYSA-N 0.000 description 1
- LJRGBERXYNQPJI-UHFFFAOYSA-M sodium;3-nitrobenzenesulfonate Chemical compound [Na+].[O-][N+](=O)C1=CC=CC(S([O-])(=O)=O)=C1 LJRGBERXYNQPJI-UHFFFAOYSA-M 0.000 description 1
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 1
- 230000009870 specific binding Effects 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 230000001256 tonic effect Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 230000000304 vasodilatating effect Effects 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 239000008096 xylene Substances 0.000 description 1
Landscapes
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Description
〔産業上の利用分野〕
本発明は抗不安薬などの医薬として有用ベンゾ
チエピノ〔5,4−c〕ピリダジン化合物に関す
る。
〔従来の技術〕
現在、神経症、うつ病や各種疾患における不
安、緊張などの疾病を改善、治療するための抗不
安薬としてジアゼパムなどのベンゾジアゼピン系
化合物が用いられている。しかしながら、このベ
ンゾジアゼピン化合物はさらに、鎮静作用、筋弛
緩作用、抗痙攣作用、アルコール増強作用、麻酔
増強作用などの薬理作用を有することから、眠
気、ふらつき、注意力・集中力・反射運動能力な
どの低下などが副作用として問題になることが多
い。
このことから近年これら副作用が弱いか、また
はない、より選択的な抗不安薬の開発が進んでい
る。
このような抗不安薬の研究において、脳内ベン
ゾジアゼピン受容体に親和性を示す非ベンゾジア
ゼピン系化合物(特開昭61−40285号など)が提
供されてきているが、依然として作用の選択性が
不十分であるとか、安全性が低いなどの解決すべ
き課題がある。
ところで、縮合ピリダジン化合物が種々の薬理
作用を有していることは公知である。特に国際出
願WO86/01506には抗不安作用をを有する9−
クロロ−2−フエニル−4,4a,5,6−テト
ラヒドロベンゾ〔h〕シンノリン−3(2H)−オ
ンなどの化合物が、ヨーロツパ特許出願公開第
124314号明細書および米国特許第4602019号明細
書には強心作用および抗高血圧作用を有する2,
4,4a,5−テトラヒドロ−7−(1H−イミダゾ
ール−1−イル)−3H−インデノ〔1,2−c〕
ピリダジン−3−オンなどの化合物が、またヨー
ロツパ特許出願公開第169443号明細書および米国
特許第4692447号明細書には降圧作用、血管拡張
作用、抗凝集作用、抗血栓作用および細胞防御作
用を有する8−アミノ−2−n−ブチル−2,
4,4a,5,6,7−ヘキサヒドロ−3H−ベン
ゾ〔6,7〕シクロヘプテン〔1,2−c〕−ピ
リダジン−3−オンなどの化合物が開示されてい
る。
〔発明が解決しようとする課題〕
本発明者らは選択的かつ安全性の高い非ベンゾ
ジアゼピン系抗不安薬を開発することを目的とし
て、鋭意研究を続けてきた。
〔課題を解決するための手段〕
本発明者らの研究により、選択的で、かつすぐ
れた抗不安作用を有し、さらに低毒性のベンゾチ
エピノ〔5,4−c〕ピリダジン化合物を見出す
に至つた。
本発明は一般式
(式中、R1,R2は同一または異なつて水素、ハ
ロゲン、トリフルオロメチル、ヒドロキシ、アミ
ノ、ニトロ、シアノ、C1-4アルキル、C1-4アルコ
キシまたはC2-5アルカノイルアミノを、R3は水
素、C1-8アルキル、ヒドロキシ−C1-4アルキル、
C2-5アルカノイルオキシ−C1-4アルキル、アリー
ル、アリール−C1-4アルキル、ヘテロアリールま
たは芳香環上にハロゲン、トリフルオロメチル、
ヒドロキシ、アミノ、ニトロ、シアノ、C1-4アル
キル、C1-4アルコキシおよびC2-5アルカノイルア
ミノから選ばれる置換基を1〜3個有するアリー
ル、アリール−C1-4アルキルもしくはヘテロアリ
ールを、nは0,1または2を、4位と4a位と
の間の結合―――………は単結合または二重結合を示
す。)
で表わされるベンゾチエピノ〔5,4−c〕ダジ
ン化合物に関する。
一般式()の記号を定義により説明すると、
ハロゲンとはフツ素、塩素、臭素、ヨウ素を、
C1-4アルキルとはメチル、エチル、プロピル、イ
ソプロピル、ブチル、イソブチル、第3級ブチル
などを、C1-4アルコキシとはメトキシ、エトキ
シ、プロポキシ、イソプロポキシ、ブトキシ、イ
ソブトキシ、第3級ブトキシなどを、C2-5アルカ
ノイルアミノとはアセチルアミノ、プロピオニル
アミノ、ブチリルアミノ、ピバロイルアミノなど
を、ヒドロキシ−C1-4アルキルとはヒドロキシメ
チル、ヒドロキシエチル、ヒドロキシプロピル、
ヒドロキシブチルなどを、C2-5アルカノイルオキ
シ−C1-4アルキルとはアセトキシメチル、アセト
キシエチル、アセトキシプロピル、アセトキシブ
チル、プロピオニルオキシメチル、プヨピオニル
オキシエチル、プロピオニルオキシプロピル、プ
ロピオニルオキシブチルなどを、C1-8アルキルと
は直鎖または分枝鎖状で、メチル、エチル、プロ
ピル、イソプロピル、ブチル、第2級ブチル、第
3級ブチル、ペンチル、イソペンチル、ネオペン
チル、ヘキシル、ヘプチル、オクチル、2−エチ
ルヘキシルなどを、アリール−C1-4アルキルとは
ベンジル、フエニルエチル、フエニルプロピル、
フエニルブチル、ナフチルメチル、ナフチルエチ
ル、ナフチルプロピル、ナフチルブチルなどを、
アリールとはフエニル、ナフチルなどを、ヘテロ
アリールとは2−ピリジル、3−ピリジル、4−
ピリジル、2−チエニル、3−チエニル、2−フ
リル、3−フリルなどを、芳香環上にハロゲン、
トリフルオロメチル、ヒドロキシ、アミノ、ニト
ロ、シアノ、C1-4アルキル、C1-4アルコキシおよ
びC2-5アルカノイルアミノから選ばれる置換基を
1〜3個有するアリール、アリール−C1-4アルキ
ルもしくはヘテロアリールとは2−クロロフエニ
ル、3−クロロフエニル、4−クロロフエニル、
3,4−ジクロロフエニル、4−プロモフエニ
ル、4−フルオロフエニル、3−トリフルオロメ
チルフエニル、4−ヒドロキシフエニル、4−ア
ミノフエニル、4−シアノフエニル、4−メチル
フエニル、4−メトキシフエニル、4−アセチル
アミノフエニル、4−プロピオニルアミノフエニ
ル、3,4,5−トリメトキシフエニル、4−ク
ロロベンジル、4−メチルベンジル、2,3−ジ
クロロベンジル、4−メトキシベンジル、4−ヒ
ドロキシベンジル、3,4,5−トリメトキシベ
ンジル、2−(4−クロロフエニル)エチル、4
−(4−クロロフエニル)ブチル、5−クロロ−
2−ピリジル、4,5−ジクロロ−2−ピリジ
ル、5−メチル−2−チエニル、5−メチル−3
−チエニル、5−クロロ−2−チエニル、5−ク
ロロ−2−フリルなどを示す。
本発明の化合物()が不斉炭素原子を有する
場合にはラセミ体混合物または光学異性体の形で
得ることができ、さらに化合物()が少なくと
も2個の不斉原子を有する場合には、個々のジア
ステレオマーまたはそれらの混合物として得られ
る。本発明はこれらの混合物および個々の異性体
をも包含する。また、本発明は立体異性体をも包
含する。
本発明の好ましい化合物としては2−(4−ク
ロロフエニル)−5,6−ジヒドロ−〔〕ベンゾ
チエピノ〔5,4−c〕ピリダジン−3(2H)−
オン、10−クロロ−2−(4−クロロフエニル)−
5,6−ジヒドロ−〔〕ベンゾチエピノ〔5,
4−c〕ピリダジン−3(2H)−オン、7−オキ
シド、2−(4−クロロフエニル)−5,6−ジヒ
ドロ−〔1〕ベンゾチエピノ〔5,4−c〕ピリ
ダジン−3(2H)−オン・7−オキシド、2−(4
−クロロフエニル)−4,4a,5,6−テトラヒ
ドロ−〔1〕ベンゾチエピノ〔5,4−c〕ピリ
ダジン−3(2H)−オン・7−オキシド、2−(4
−クロロフエニル)−10−フルオロ−5,6−ジ
ヒドロ−〔1〕ベンゾチエピノ〔5,4−c〕ピ
リダジン−3(2H)−オン、2−(4−クロロフエ
ニル)−10−フルオロ−5,6−ジヒドロ−〔1〕
ベンゾチエピノ〔5,4−c〕ピリダジン−3
(2H)−オン・7−オキシド、2−(4−ブロモフ
エニル)−5,6−ジヒドロ−〔1〕ベンゾチエピ
ノ〔5,4−c〕ピリダジン−3(2H)−オン・
7−オキシド、2−(4−ブロモフエニル)−4,
4a,5,6−テトラヒドロ−〔1〕ベンゾチエピ
ノ〔5,4−c〕ピリダジン−3(2H)−オン・
7−オキシド、10−フルオロ−2−(4−フルオ
ロフエニル)−5,6−ジヒドロ−〔1〕ベンゾチ
エピノ〔5,4−c〕ピリダジン−3(2H)−オ
ン、8−クロロ−2−(4−クロロフエニル)−
5,6−ジヒドロ−〔1〕ベンゾチエピノ〔5,
4−c〕ピリダジン−3(2H)−オン・7−オキ
シド、10−フルオロ−2−(4−フルオロフエニ
ル)−5,6−ジヒドロ−〔1〕ベンゾチエピノ
〔5,4−c〕ピリダジン−3(2H)−オン・7−
オキシドなどがあげられる。
本発明において一般式()の化合物は、たと
えば以下に示す方法によつて合成することができ
る。
方法 (i)
一般式
(式中、各記号は前記と同義である。)
で表わされる化合物と、一般式
R3−NHNH2 ()
(式中、R3は前記と同義である。)
で表わされるヒドラジン誘導体またはその水和物
あるいは酸化加塩とを反応させて得られる一般式
(式中、各記は前記と同義である。)
で表わされる化合物を閉環反応に付す方法。
反応は適当な溶媒、たとえばメタノール、エタ
ノール、プロパノールなどのアルコール系溶媒
中、5〜20時間加熱還流することにより進行し、
一般式()および一般式()の化合物を生ず
る。
一般式()のヒドラジン誘導体が酸付加塩の
場合、脱酸剤(酢酸ナトリウム、酢酸カリウム、
炭酸水素ナトリウム、炭酸ナトリウム、炭酸カリ
ウムなど)の存在下に反応させる。一般式()
の化合物が得られた場合には、酢酸中5〜10時間
加熱還流することにより一般式()の化合物を
得ることができる。
方法 (ii)
一般式()においてn=0の化合物を酸化反
応に付すことにより一般式()中、n=1また
は2の化合物、すなわちオキシドまたはジオキシ
ド化合物を合成する方法。
反応は適当な溶媒中、酸化剤(過酢酸、過安息
香酸、m−クロロ過安息香酸、亜臭素酸ナトリウ
ム・3水和物など)の存在下10〜100℃に1〜10
時間保つことにより進行するが、酢酸溶媒中、過
酸化水素の存在下、室温に1〜5時間保つとn=
1の化合物が優先的に得られ、30〜100℃に2〜
10時間保つことによりn=2の化合物が得られ
る。
方法 (iii)
一般式()においてR3が水素である化合物
と一般式
R4−X ()
〔式中、R4はC1-8アルキル、ヒドロキシ−
C1-4アルキル、C2-5アルカノイルオキシ−C1-4ア
ルキル、アリール−C1-4アルキルまたは芳香環上
に置換基を有するアリール−C1-4アルキルを、X
は反応活性な原子または基(塩素、臭素などのハ
ロゲンまたはメタンスルホニルオキシ、トリエン
スルホニルオキシ、ベンゼンスルホニルオキシな
ど)を示す。〕
で表わされる化合物を反応させ、R3がC1-8アル
キル、ヒドロキシ−C1-4アルキル、C2-5アルカノ
イルオキシ−C1-4アルキル、アリール−C1-4アル
キルまたは芳香環上に置換基を有するアリール−
C1-4アルキルである化合物を製造する方法。
反応は適当な溶媒、たとえばベンゼ、トルエ
ン、キシレンなどの非極性溶媒、あるいはN、N
−ジメチルホルムアミド、アセトニトリルなどの
極性溶媒中、脱酸剤(水素化ナトリウム、ナトリ
ウムアミド、ナトリウムメトキシド、ナトリウム
エトキシド、水酸化カリウム、水酸化ナトリウム
など)の存在下、0〜50℃で1〜10時間保つこと
により進行する。
方法 (iv)
一般式()において4位と4a位との間の結
合が二重結合である場合は、その結合部位が単結
合である化合物に酢酸溶媒中、臭素を滴下するこ
とにより〔ジヤーナル・オブ・メデイシナル・ケ
ミストリー(J.Med.Chem)第14巻、262頁
(1971年)〕合成することができる。反応は酢酸溶
媒中、1〜1.5倍モル量の臭素を20〜60℃で適下
すると好適に進行する。
また、4位と4a位との間の結合が二重結合で
ある一般式()の化合物はその結合部位が単結
合である化合物にナトリウム−m−ニトロベンゼ
ンスルホネート(Bachmann法、英国特許第
1168291号明細書)を反応させることによつても
も合成することができる。
方法 (v)
上記方法(i)から(iv)により得られた化合物の基
R1,R2または基R3のの置換基を、通常の有機化
学的手法によつて他の基に交換する方法。
そのような方法としては、たとえばニトロ基を
アミノ基に還元する方法、アミノ基を低級アルカ
ノイル化する方法またはアミノ基をシアノ基に変
換する方法(ザンドマイヤー反応、ガツターマン
反応など)があげられる。
このようにして得られる本発明化合物は再結晶
法、カラムクロマト法などの常法により単離精製
することができる。
得られる生成物ががラセミ体であるときは、た
とえば光学活性な酸との塩の分別再結晶により、
もしくは光学活性な担体を充填したカラムをを通
すことにより所望の光学異性体に分割することが
できる。個々のジアステレオマーは分別結晶化、
クロマトグラフイーなどの手段によつて分離する
ことができる。これらは光学活性な原料化合物な
どを用いることによつても得られる。また、立体
異性体は再結晶法、カラムクロマト法などにより
単離することができる。
次に、本発明に包含される実施例記載以外の化
合物をを以下に例示する。
◎10ーフルオロ−2−(4−メトキシフエニル)−
4,4a,5,6−テトラヒドロ〔1〕ベンゾ
チエピノ〔5,4ーc)ピリダジンー3(2H)
−オン
◎8ークロロ−2−(4−メチルフエニル)−4,
4a,5,6−テトラヒドロ〔1〕ベンゾチエ
ピノ〔5,4ーc)ピリダジンー3(2H)−オ
ン
◎8−クロロ−2−(4−クロロフエニル)−4,
4a,5,6−テトラヒドロ〔1〕ベンゾチエ
ピノ〔5,4ーc)ピリダジンー3(2H)−オ
ン
◎9−クロロ−2−(4−クロロフエニル)−4,
4a,5,6−テトラヒドロ〔1〕ベンゾチエ
ピノ〔5,4ーc)ピリダジンー3(2H)−オ
ン
◎9−クロロ−2−(4−メチルフエニル)−4,
4a,5,6−テトラヒドロ〔1〕ベンゾチエ
ピノ〔5,4ーc)ピリダジンー3(2H)−オ
ン
◎2−(4−クロロフエニル)−10−メトキシ−
4,4a,5,6−テトラヒドロ〔1〕ベンゾ
チエピノ〔5,4ーc)ピリダジンー3(2H)
−オン
◎10−メトキシ−2−(4−クロロフエニル)−
4,4a,5,6−テトラヒドロ〔1〕ベンゾ
チエピノ〔5,4ーc)ピリダジンー3(2H)
−オン
◎10−ヒドロキシ−2−(4−メチルフエニル)−
4,4a,5,6−テトラヒドロ〔1〕ベンゾ
チエピノ〔5,4ーc)ピリダジンー3(2H)
−オン
◎10−ニトロ−4,4a,5,6−テトラヒドロ
〔1〕ベンゾチエピノ〔5,4ーc)ピリダジ
ンー3(2H)−オン
◎10−ニトロ−2−フエニル−4,4a,5,6
−テトラヒドロ〔1〕ベンゾチエピノ〔5,4
ーc)ピリダジンー3(2H)−オン
◎10−アミノ−4,4a,5,6−テトラヒドロ
〔1〕ベンゾチエピノ〔5,4ーc)ピリダジ
ンー3(2H)−オン
◎10−アミノ−2−フエニル−4,4a,5,6
−テトラヒドロ〔1〕ベンゾチエピノ〔5,4
ーc)ピリダジンー3(2H)−オン
◎10−シアノ−4,4a,5,6−テトラヒドロ
〔1〕ベンゾチエピノ〔5,4ーc)ピリダジ
ンー3(2H)−オン
◎10−アセチルアミノ−4,4a,5,6−テト
ラヒドロ〔1〕ベンゾチエピノ〔5,4ーc)
ピリダジンー3(2H)−オン
◎10−アセチルアミノ−2−フエニル−4,4a,
5,6−テトラヒドロ〔1〕ベンゾチエピノ
〔5,4ーc)ピリダジンー3(2H)−オン
◎2−(2−ヒドロキシエチル)−4,4a,5,
6−テトラヒドロ〔1〕ベンゾチエピノ〔5,
4ーc)ピリダジンー3(2H)−オン
◎2−(3−アセトキシプロピル)−4,4a,5,
6−テトラヒドロ〔1〕ベンゾチエピノ〔5,
4ーc)ピリダジンー3(2H)−オン
◎2−(1−アセトキシブチル)−4,4a,5,
6−テトラヒドロ〔1〕ベンゾチエピノ〔5,
4ーc)ピリダジンー3(2H)−オン
◎2−ブチル−4,4a,5,6−テトラヒドロ
〔1〕ベンゾチエピノ〔5,4ーc)ピリダジ
ンー3(2H)−オン
◎2−ヘキシル−4,4a,5,6−テトラヒド
ロ〔1〕ベンゾチエピノ〔5,4ーc)ピリダ
ジンー3(2H)−オン
◎2−(3−トリフルオロメチルフエニル)−4,
4a,5,6−テトラヒドロ〔1〕ベンゾチエ
ピノ〔5,4ーc)ピリダジンー3(2H)−オ
ン
◎2−(−ヒドロキシフエニル)−4,4a,5,
6−テトラヒドロ〔1〕ベンゾチエピノ〔5,
4ーc)ピリダジンー3(2H)−オン
◎2−(4−ニトロフエニル)−4,4a,5,6
−テトラヒドロ〔1〕ベンゾチエピノ〔5,4
ーc)ピリダジンー3(2H)−オン
◎2−(4−アミノフエニル)−4,4a,5,6
−テトラヒドロ〔1〕ベンゾチエピノ〔5,4
ーc)ピリダジンー3(2H)−オン
◎2−(4−シアノフエニル)−4,4a,5,6
−テトラヒドロ〔1〕ベンゾチエピノ〔5,4
ーc)ピリダジンー3(2H)−オン
◎2−(4−アセチルアミノフエニル)−4,4a,
5,6−テトラヒドロ〔1〕ベンゾチエピノ
〔5,4ーc)ピリダジンー3(2H)−オン
◎2−(4−プロピオニルアミノフエニル)−4,
4a,5,6−テトラヒドロ〔1〕ベンゾチエ
ピノ〔5,4ーc)ピリダジンー3(2H)−オ
ン
◎2−ベンジル−4,4a,5,6−テトラヒド
ロ〔1〕ベンゾチエピノ〔5,4ーc)ピリダ
ジンー3(2H)−オン
◎2−(4−クロロベンジル)−4,4a,5,6
−テトラヒドロ〔1〕ベンゾチエピノ〔5,4
ーc)ピリダジンー3(2H)−オン
◎2−(4−チルベンジル)−4,4a,5,6−
テトラヒドロ〔1〕ベンゾチエピノ〔5,4ー
c)ピリダジンー3(2H)−オン
◎2−(2−フエニルチル)−4,4a,5,6−
テトラヒドロ〔1〕ベンゾチエピノ〔5,4ー
c)ピリダジンー3(2H)−オン
◎2−(4−フエニルブチル)−4,4a,5,6
−テトラヒドロ〔1〕ベンゾチエピノ〔5,4
ーc)ピリダジンー3(2H)−オン
◎8,10−ジメチル−2−フエニル−4,4a,
5,6−テトラヒドロ〔1〕ベンゾチエピノ
〔5,4ーc)ピリダジンー3(2H)−オン
◎2−(4−クロロフエニル)−8,10−ジメチル
−4,4a,5,6−テトラヒドロ〔1〕ベン
ゾチエピノ〔5,4ーc)ピリダジンー3
(2H)−オン
◎8,10−ジメチル−4,4a,5,6−テトラ
ヒドロ〔1〕ベンゾチエピノ〔5,4ーc)ピ
リダジンー3(2H)−オン
◎8,11−ジメチル−4,4a,5,6−テトラ
ヒドロ〔1〕ベンゾチエピノ〔5,4ーc)ピ
リダジンー3(2H)−オン
◎8,11−ジメチル−2−フエニル−4,4a,
5,6−テトラヒドロ〔1〕ベンゾチエピノ
〔5,4ーc)ピリダジンー3(2H)−オン
◎2−(5−メチル−2−チエニル)−4,4a,
5,6−テトラヒドロ〔1〕ベンゾチエピノ
〔5,4ーc)ピリダジンー3(2H)−オン
◎2−(5−メチル−3−チエニル)−4,4a,
5,6−テトラヒドロ〔1〕ベンゾチエピノ
〔5,4ーc)ピリダジンー3(2H)−オン
◎2−(5−メチル−2−チエニル)−5,6−ジ
ヒドロ−〔1〕ベンゾチエピノ〔5,4−c〕
ピリダジン−3(2H)−オン
◎2−(5−メチル−2−チエニル)−5,6−ジ
ヒドロ−〔1〕ベンゾチエピノ〔5,4−c〕
ピリダジン−3(2H)−オン
◎2−(5−メチル−2−チエニル)−5,6−ジ
ヒドロ−〔1〕ベンゾチエピノ〔5,4−c〕
ピリダジン−3(2H)−オン・7−オキシド
◎2−(5−メチル−3−チエニル)−5,6−ジ
ヒドロ−〔1〕ベンゾチエピノ〔5,4−c〕
ピリダジン−3(2H)−オン・7−オキシド
◎2−(5−メチル−2−チエニル)−4,4a,
5,6−テトラヒドロ〔1〕ベンゾチエピノ
〔5,4ーc)ピリダジンー3(2H)−オン・
7,7−ジオキシド
◎2−(5−メチル−3−チエニル)−4,4a,
5,6−テトラヒドロ〔1〕ベンゾチエピノ
〔5,4ーc)ピリダジンー3(2H)−オン・
7,7−ジオキシド
◎2−(5−メチル−2−チエニル)−5,6−ジ
ヒドロ−〔1〕ベンゾチエピノ〔5,4−c〕
ピリダジン−3(2H)−オン・7,7−ジオキ
シド
◎2−(5−メチル−3−チエニル)−5,6−ジ
ヒドロ−〔1〕ベンゾチエピノ〔5,4−c〕
ピリダジン−3(2H)−オン・7,7−ジオキ
シド
本発明における一般式()の化合物は文献未
載の新規化合物であり、たとえば一般式
(式中、各記号は前記と同義である。)
で表わされる化合物に、アセトン中、ヨウ化メチ
ルを加え、室温で2〜5時間保持することによつ
て第4級アンモニウム化合物とする。これをメタ
ノールあるいはジメチルホルムアミド中、シアン
化カリウムまたはシアン化ナトリウムを加えて、
40〜50℃で4〜8時間反応させて一般式
(式中、各記号は前記と同義である。)
で表わされるシアノ体とし、さらに酢酸および濃
塩酸を加え、80〜100℃で8〜10時間保つことに
よつて、一般式
(式中、各記号は前記と同義である。)
の化合物が得られる。
参考までに化合物(′)の代表例を物理恒数
とともに示す。
◎5−オキソ−2,3,4,5−テトラヒドロ−
〔1〕ベンゾチエピン−4−酢酸、融点164〜
167℃
◎7−クロロ−5−オキシ−2,3,4,5−テ
トラヒドロ−〔1〕ベンゾチエピン−4−酢酸、
融点203〜205℃
◎7−フルオロ−5−オキソ−2,3,4,5−
テトラヒドロ−〔1〕ベンゾチエピン−4−酢
酸、融点191〜193℃
◎7−メチル−5−オキソ−2,3,4,5−テ
トラヒドロ−〔1〕ベンゾチエピン−4−酢酸、
融点200〜202℃
〔作用および発明の効果〕
以下に本発明化合物の有用性を説明するため
に、薬理作用を実験方法とともに示す。
試験に用いた化合物は次の通りである。
化合物A:2−(4−クロロフエニル)−5,6
−ジヒドロ−〔1〕ベンゾチエピノ〔5,4−c〕
ピリダジン−3(2H)−オン
化合物B:10−クロロ−2−(4−クロロフエ
ニル)−5,6−ジヒドロ−〔1〕ベンゾチエピノ
〔5,4−c〕ピリダジン−3(2H)−オン・7−
オキシド
化合物C:2−(4−クロロフエニル)−5,6
−ジヒドロ−〔1〕ベンゾチエピノ〔5,4−c〕
ピリダジン−3(2H)−オン・7−オキシド
化合物D:2−(4−クロロフエニル)−4,
4a,5,6−テトラヒドロ〔1〕ベンゾチエピ
ノ〔5,4ーc)ピリダジンー3(2H)−オン・
7−オキシド
化合物E:2(4−クロロフエニル)−10フルオ
ロ−5,6−ジヒドロ−〔1〕ベンゾチエピノ
〔5,4−c〕ピリダジン−3(2H)−オン
化合物F:2−(4−クロロフエニル)−10−フ
ルオロ−5,6−ジヒドロ−〔1〕ベンゾチエピ
ノ〔5,4−c〕ピリダジン−3(2H)−オン・
7−オキシド
化合物G:2−(4−ブロモフエニル)−5,6
−ジヒドロ−〔1〕ベンゾチエピノ〔5,4−c〕
ピリダジン−3(2H)−オン・7−オキシド
化合物H:2−(4−ブロモフエニル)4,
4a,5,6−テトラヒドロ〔1〕ベンゾチエピ
ノ〔5,4ーc)ピリダジンー3(2H)−オン・
7−オキシド
化合物I:10−フルオロ−2−(4−フルオロ
フエニル)−5,6−ジヒドロ−〔1〕ベンゾチエ
ピノ〔5,4−c〕ピリダジン−3(2H)−オン
化合物J:8−クロロ−2−(4−クロロフエ
ニル)−5,6−ジヒドロ−〔1〕ベンゾチエピノ
〔5,4−c〕ピリダジン−3(2H)−オン・7−
オキシド
実験例 1
ベンゾジアゼピン受容体に対する置換能
特異的ベンゾジアゼピン受容体結合力試験をを
ライフ・サイエンス(Life Science)第20巻、
2101頁(1977年)の方法に準じて行なつた。
9〜10週令のウイスター系雄性ラツトの大脳皮
質より粗シナプトソーム画分を分離し、120mM
塩化ナトリウムおよび5mM塩化カリウムを含む
50mMトリス−塩酸緩衝液(PH7.4)に懸濁して
実験に用いた。次に、シナプトソーム懸濁液に数
種類の濃度の試験化合物とトリチウム化ジアゼパ
ム(最終濃度2nM)を加え、0℃で20分間反応
させた。その後、この懸濁液をホワツトマン
(Whatman)GF/Bグラスフアイバーフイルタ
ーで濾過し、上記緩衝液でフイルターを洗つた
後、フイルター上に残つた放射能活性を液体シン
チレーシヨンカウンターで測定した。
特異的結合量は、総結合量から10-6Mの非放射
性ジアゼパムの存在下で得られた結合量を差し引
いた値とした。試験化合物のベンゾジアゼピン受
容に対する親和力は、トリチウム化ジアゼパムを
その結合部位から置換する能力によつて評価され
るものであり、Ki値で表わされる。
第1表に試験結果を示す。
実験例 2
抗ビククリン作用
ライフ・サイエンス(Life Science)第21巻、
1779頁(1977年)の方法に準じて抗ビククリン作
用試験を行つた。
体重20〜28gの雄性ddYマウスを1群7〜14匹
として使用した。試験化合物を経口投与して1時
間後に、(+)ビククリン0.6mg/Kgを静脈内投与
し5分以内の強直性伸展痙攣の発現の有無を調
べ、50%有効濃度(ED50値)を求めた。
第1表に試験結果を示す。
[Industrial Application Field] The present invention relates to benzothiepino[5,4-c]pyridazine compounds useful as pharmaceuticals such as anxiolytics. [Prior Art] Currently, benzodiazepine compounds such as diazepam are used as anxiolytic drugs to improve and treat diseases such as neurosis, depression, and anxiety and tension in various diseases. However, benzodiazepine compounds also have pharmacological effects such as sedation, muscle relaxation, anticonvulsant effects, alcohol-enhancing effects, and anesthesia-enhancing effects, which can lead to problems such as drowsiness, light-headedness, attention, concentration, and reflex movement ability. Decreased blood pressure is often a problem as a side effect. For this reason, in recent years there has been progress in the development of more selective anxiolytic drugs that have weak or no side effects. In research into such anxiolytics, non-benzodiazepine compounds (such as Japanese Patent Application Laid-open No. 61-40285) that show affinity for benzodiazepine receptors in the brain have been provided, but the selectivity of action is still insufficient. There are issues that need to be resolved, such as safety and low safety. By the way, it is known that fused pyridazine compounds have various pharmacological actions. In particular, international application WO86/01506 describes 9-
Compounds such as chloro-2-phenyl-4,4a,5,6-tetrahydrobenzo[h]cinnolin-3(2H)-one have been disclosed in European patent application publication no.
124314 and U.S. Patent No. 4602019 disclose 2, which has cardiotonic and antihypertensive effects.
4,4a,5-tetrahydro-7-(1H-imidazol-1-yl)-3H-indeno[1,2-c]
Compounds such as pyridazin-3-ones have also been shown to have antihypertensive, vasodilating, antiaggregating, antithrombotic, and cytoprotective effects as described in European Patent Application No. 169,443 and US Pat. No. 4,692,447. 8-amino-2-n-butyl-2,
Compounds such as 4,4a,5,6,7-hexahydro-3H-benzo[6,7]cycloheptene[1,2-c]-pyridazin-3-one are disclosed. [Problems to be Solved by the Invention] The present inventors have continued intensive research with the aim of developing a selective and highly safe non-benzodiazepine anxiolytic drug. [Means for Solving the Problems] Through research conducted by the present inventors, we have discovered a benzothiepino[5,4-c]pyridazine compound that has selective and excellent anxiolytic effects and is low in toxicity. . The present invention is based on the general formula (In the formula, R 1 and R 2 are the same or different and represent hydrogen, halogen, trifluoromethyl, hydroxy, amino, nitro, cyano, C 1-4 alkyl, C 1-4 alkoxy or C 2-5 alkanoylamino, R 3 is hydrogen, C 1-8 alkyl, hydroxy-C 1-4 alkyl,
C 2-5 alkanoyloxy-C 1-4 alkyl, aryl, aryl-C 1-4 alkyl, heteroaryl or halogen on the aromatic ring, trifluoromethyl,
Aryl, aryl-C 1-4 alkyl or heteroaryl having 1 to 3 substituents selected from hydroxy, amino, nitro, cyano, C 1-4 alkyl, C 1-4 alkoxy and C 2-5 alkanoylamino , n represents 0, 1 or 2, and the bond between the 4th and 4a positions represents a single bond or a double bond. ) It relates to a benzothiepino[5,4-c]dazine compound represented by: To explain the symbols in the general formula () by definition,
Halogens include fluorine, chlorine, bromine, and iodine.
C 1-4 alkyl refers to methyl, ethyl, propyl, isopropyl, butyl, isobutyl, tertiary butyl, etc., and C 1-4 alkoxy refers to methoxy, ethoxy, propoxy, isopropoxy, butoxy, isobutoxy, tertiary butoxy. C 2-5 alkanoylamino means acetylamino, propionylamino, butyrylamino, pivaloylamino, etc. Hydroxy-C 1-4 alkyl means hydroxymethyl, hydroxyethyl, hydroxypropyl,
Hydroxybutyl, etc., C 2-5 alkanoyloxy-C 1-4 alkyl includes acetoxymethyl, acetoxyethyl, acetoxypropyl, acetoxybutyl, propionyloxymethyl, propionyloxyethyl, propionyloxypropyl, propionyloxybutyl, etc. , C 1-8 alkyl is a straight or branched chain, and includes methyl, ethyl, propyl, isopropyl, butyl, secondary butyl, tertiary butyl, pentyl, isopentyl, neopentyl, hexyl, heptyl, octyl, 2 -ethylhexyl, etc., aryl-C 1-4 alkyl means benzyl, phenylethyl, phenylpropyl,
Phenylbutyl, naphthylmethyl, naphthylethyl, naphthylpropyl, naphthylbutyl, etc.
Aryl refers to phenyl, naphthyl, etc.; heteroaryl refers to 2-pyridyl, 3-pyridyl, 4-pyridyl, etc.
Halogen, pyridyl, 2-thienyl, 3-thienyl, 2-furyl, 3-furyl, etc. on the aromatic ring,
Aryl, aryl-C 1-4 alkyl having 1 to 3 substituents selected from trifluoromethyl, hydroxy, amino, nitro, cyano, C 1-4 alkyl, C 1-4 alkoxy and C 2-5 alkanoylamino Or heteroaryl is 2-chlorophenyl, 3-chlorophenyl, 4-chlorophenyl,
3,4-dichlorophenyl, 4-promophenyl, 4-fluorophenyl, 3-trifluoromethylphenyl, 4-hydroxyphenyl, 4-aminophenyl, 4-cyanophenyl, 4-methylphenyl, 4-methoxyphenyl, 4-acetylaminophenyl, 4-propionylaminophenyl, 3,4,5-trimethoxyphenyl, 4-chlorobenzyl, 4-methylbenzyl, 2,3-dichlorobenzyl, 4-methoxybenzyl, 4-hydroxy Benzyl, 3,4,5-trimethoxybenzyl, 2-(4-chlorophenyl)ethyl, 4
-(4-chlorophenyl)butyl, 5-chloro-
2-pyridyl, 4,5-dichloro-2-pyridyl, 5-methyl-2-thienyl, 5-methyl-3
-thienyl, 5-chloro-2-thienyl, 5-chloro-2-furyl, etc. When the compound () of the present invention has an asymmetric carbon atom, it can be obtained in the form of a racemic mixture or an optical isomer, and when the compound () has at least two asymmetric atoms, it can be obtained individually. diastereomers or mixtures thereof. The invention also includes mixtures and individual isomers thereof. The present invention also includes stereoisomers. Preferred compounds of the present invention include 2-(4-chlorophenyl)-5,6-dihydro-[]benzothiepino[5,4-c]pyridazine-3(2H)-
on, 10-chloro-2-(4-chlorophenyl)-
5,6-dihydro-[]benzothiepino[5,
4-c]pyridazin-3(2H)-one, 7-oxide, 2-(4-chlorophenyl)-5,6-dihydro-[1]benzothiepino[5,4-c]pyridazin-3(2H)-one・7-oxide, 2-(4
-chlorophenyl)-4,4a,5,6-tetrahydro-[1]benzothiepino[5,4-c]pyridazin-3(2H)-one 7-oxide, 2-(4
-chlorophenyl)-10-fluoro-5,6-dihydro-[1]benzothiepino[5,4-c]pyridazin-3(2H)-one, 2-(4-chlorophenyl)-10-fluoro-5,6- Dihydro-[1]
Benzothiepino[5,4-c]pyridazine-3
(2H)-one 7-oxide, 2-(4-bromophenyl)-5,6-dihydro-[1]benzothiepino[5,4-c]pyridazin-3(2H)-one
7-oxide, 2-(4-bromophenyl)-4,
4a,5,6-tetrahydro-[1]benzothiepino[5,4-c]pyridazin-3(2H)-one.
7-oxide, 10-fluoro-2-(4-fluorophenyl)-5,6-dihydro-[1]benzothiepino[5,4-c]pyridazin-3(2H)-one, 8-chloro-2- (4-chlorophenyl)-
5,6-dihydro-[1]benzothiepino[5,
4-c]pyridazin-3(2H)-one 7-oxide, 10-fluoro-2-(4-fluorophenyl)-5,6-dihydro-[1]benzothiepino[5,4-c]pyridazine- 3 (2H)-on 7-
Examples include oxides. In the present invention, the compound of general formula () can be synthesized, for example, by the method shown below. Method (i) General formula (In the formula, each symbol has the same meaning as above.) A compound represented by the general formula R 3 -NHNH 2 () (In the formula, R 3 has the same meaning as above.) A hydrazine derivative or its General formula obtained by reacting with hydrates or oxidized salts (In the formula, each symbol has the same meaning as above.) A method of subjecting a compound represented by the following to a ring-closing reaction. The reaction proceeds by heating under reflux for 5 to 20 hours in a suitable solvent, such as an alcoholic solvent such as methanol, ethanol, or propanol.
This gives rise to compounds of general formula () and general formula (). When the hydrazine derivative of general formula () is an acid addition salt, deoxidizing agents (sodium acetate, potassium acetate,
react in the presence of sodium bicarbonate, sodium carbonate, potassium carbonate, etc.). General formula ()
When a compound of general formula () is obtained, a compound of general formula () can be obtained by heating under reflux in acetic acid for 5 to 10 hours. Method (ii) A method of synthesizing a compound where n=1 or 2 in the general formula (), that is, an oxide or dioxide compound, by subjecting the compound where n=0 in the general formula () to an oxidation reaction. The reaction is carried out in an appropriate solvent in the presence of an oxidizing agent (peracetic acid, perbenzoic acid, m-chloroperbenzoic acid, sodium bromite trihydrate, etc.) at 10 to 100°C for 1 to 10 min.
It progresses by keeping it for a while, but if it is kept at room temperature in an acetic acid solvent in the presence of hydrogen peroxide for 1 to 5 hours, n=
Compound 1 was preferentially obtained and
By holding for 10 hours, a compound with n=2 is obtained. Method (iii) Compounds in which R 3 is hydrogen in general formula () and general formula R 4 -X () [wherein R 4 is C 1-8 alkyl, hydroxy-
C 1-4 alkyl, C 2-5 alkanoyloxy-C 1-4 alkyl, aryl-C 1-4 alkyl or aryl-C 1-4 alkyl having a substituent on the aromatic ring,
represents a reactive atom or group (halogen such as chlorine, bromine, methanesulfonyloxy, trienesulfonyloxy, benzenesulfonyloxy, etc.). ] A compound represented by is reacted, and R 3 is C 1-8 alkyl, hydroxy-C 1-4 alkyl, C 2-5 alkanoyloxy-C 1-4 alkyl, aryl-C 1-4 alkyl, or on an aromatic ring. Aryl having a substituent on -
A method of producing a compound that is C 1-4 alkyl. The reaction may be carried out in a suitable solvent, such as nonpolar solvents such as benzene, toluene, xylene, or N,N
- in a polar solvent such as dimethylformamide or acetonitrile in the presence of a deoxidizing agent (sodium hydride, sodium amide, sodium methoxide, sodium ethoxide, potassium hydroxide, sodium hydroxide, etc.) at 0 to 50°C. It progresses by keeping it for 10 hours. Method (iv) When the bond between the 4-position and the 4a-position in the general formula () is a double bond, by dropping bromine in an acetic acid solvent to a compound in which the bonding site is a single bond.・Of Medicinal Chemistry (J.Med.Chem) Vol. 14, p. 262 (1971)] can be synthesized. The reaction proceeds suitably when 1 to 1.5 times the molar amount of bromine is added dropwise at 20 to 60°C in an acetic acid solvent. In addition, the compound of the general formula () in which the bond between the 4-position and the 4a-position is a double bond is replaced by sodium-m-nitrobenzenesulfonate (Bachmann method, British patent No.
1168291)). Method (v) Groups of compounds obtained by methods (i) to (iv) above.
A method of replacing a substituent of R 1 , R 2 or group R 3 with another group by a conventional organic chemical method. Such methods include, for example, a method of reducing a nitro group to an amino group, a method of converting an amino group to a lower alkanoyl group, or a method of converting an amino group to a cyano group (Sandmeyer reaction, Gatterman reaction, etc.). The compound of the present invention thus obtained can be isolated and purified by conventional methods such as recrystallization and column chromatography. When the product obtained is a racemate, for example, by fractional recrystallization of a salt with an optically active acid,
Alternatively, it can be separated into desired optical isomers by passing it through a column packed with an optically active carrier. Individual diastereomers are fractionally crystallized,
It can be separated by means such as chromatography. These can also be obtained by using optically active raw material compounds. Furthermore, stereoisomers can be isolated by recrystallization, column chromatography, and the like. Next, compounds other than those described in the Examples included in the present invention are illustrated below. ◎10-fluoro-2-(4-methoxyphenyl)-
4,4a,5,6-tetrahydro[1]benzothiepino[5,4-c)pyridazine-3(2H)
-one◎8-chloro-2-(4-methylphenyl)-4,
4a,5,6-tetrahydro[1]benzothiepino[5,4-c)pyridazin-3(2H)-one ◎8-chloro-2-(4-chlorophenyl)-4,
4a,5,6-tetrahydro[1]benzothiepino[5,4-c)pyridazin-3(2H)-one ◎9-chloro-2-(4-chlorophenyl)-4,
4a,5,6-tetrahydro[1]benzothiepino[5,4-c)pyridazin-3(2H)-one ◎9-chloro-2-(4-methylphenyl)-4,
4a,5,6-tetrahydro[1]benzothiepino[5,4-c)pyridazin-3(2H)-one ◎2-(4-chlorophenyl)-10-methoxy-
4,4a,5,6-tetrahydro[1]benzothiepino[5,4-c)pyridazine-3(2H)
-one◎10-methoxy-2-(4-chlorophenyl)-
4,4a,5,6-tetrahydro[1]benzothiepino[5,4-c)pyridazine-3(2H)
-one◎10-hydroxy-2-(4-methylphenyl)-
4,4a,5,6-tetrahydro[1]benzothiepino[5,4-c)pyridazine-3(2H)
-one◎10-nitro-4,4a,5,6-tetrahydro[1]benzothiepino[5,4-c)pyridazin-3(2H)-one◎10-nitro-2-phenyl-4,4a,5,6
-tetrahydro[1]benzothiepino[5,4
-c) Pyridazin-3(2H)-one◎10-amino-4,4a,5,6-tetrahydro[1]benzothiepino[5,4-c)pyridazin-3(2H)-one◎10-amino-2-phenyl -4, 4a, 5, 6
-tetrahydro[1]benzothiepino[5,4
-c) Pyridazin-3(2H)-one◎10-cyano-4,4a,5,6-tetrahydro[1]benzothiepino[5,4-c)pyridazin-3(2H)-one◎10-acetylamino-4, 4a,5,6-tetrahydro[1]benzothiepino[5,4-c]
Pyridazin-3(2H)-one ◎10-acetylamino-2-phenyl-4,4a,
5,6-tetrahydro[1]benzothiepino[5,4-c)pyridazin-3(2H)-one ◎2-(2-hydroxyethyl)-4,4a,5,
6-tetrahydro[1]benzothiepino[5,
4-c) Pyridazine-3(2H)-one ◎2-(3-acetoxypropyl)-4,4a,5,
6-tetrahydro[1]benzothiepino[5,
4-c) Pyridazine-3(2H)-one ◎2-(1-acetoxybutyl)-4,4a,5,
6-tetrahydro[1]benzothiepino[5,
4-c) Pyridazin-3(2H)-one ◎2-butyl-4,4a,5,6-tetrahydro[1]benzothiepino[5,4-c)pyridazin-3(2H)-one ◎2-hexyl-4, 4a,5,6-tetrahydro[1]benzothiepino[5,4-c)pyridazin-3(2H)-one ◎2-(3-trifluoromethylphenyl)-4,
4a,5,6-tetrahydro[1]benzothiepino[5,4-c)pyridazin-3(2H)-one◎2-(-hydroxyphenyl)-4,4a,5,
6-tetrahydro[1]benzothiepino[5,
4-c) Pyridazine-3(2H)-one ◎2-(4-nitrophenyl)-4,4a,5,6
-tetrahydro[1]benzothiepino[5,4
-c) Pyridazine-3(2H)-one ◎2-(4-aminophenyl)-4,4a,5,6
-tetrahydro[1]benzothiepino[5,4
-c) Pyridazine-3(2H)-one ◎2-(4-cyanophenyl)-4,4a,5,6
-tetrahydro[1]benzothiepino[5,4
-c) Pyridazine-3(2H)-one ◎2-(4-acetylaminophenyl)-4,4a,
5,6-tetrahydro[1]benzothiepino[5,4-c)pyridazin-3(2H)-one ◎2-(4-propionylaminophenyl)-4,
4a,5,6-tetrahydro[1]benzothiepino[5,4-c) pyridazin-3(2H)-one ◎2-benzyl-4,4a,5,6-tetrahydro[1]benzothiepino[5,4-c] Pyridazine-3(2H)-one ◎2-(4-chlorobenzyl)-4,4a,5,6
-tetrahydro[1]benzothiepino[5,4
-c) Pyridazine-3(2H)-one ◎2-(4-Tylbenzyl)-4,4a,5,6-
Tetrahydro[1]benzothiepino[5,4-c)pyridazin-3(2H)-one ◎2-(2-phenylthyl)-4,4a,5,6-
Tetrahydro[1]benzothiepino[5,4-c)pyridazin-3(2H)-one◎2-(4-phenylbutyl)-4,4a,5,6
-tetrahydro[1]benzothiepino[5,4
-c) Pyridazine-3(2H)-one ◎8,10-dimethyl-2-phenyl-4,4a,
5,6-tetrahydro[1]benzothiepino[5,4-c)pyridazin-3(2H)-one◎2-(4-chlorophenyl)-8,10-dimethyl-4,4a,5,6-tetrahydro[1] Benzothiepino[5,4-c)pyridazine-3
(2H)-one◎8,10-dimethyl-4,4a,5,6-tetrahydro[1]benzothiepino[5,4-c)pyridazin-3(2H)-one◎8,11-dimethyl-4,4a, 5,6-tetrahydro[1]benzothiepino[5,4-c)pyridazin-3(2H)-one ◎8,11-dimethyl-2-phenyl-4,4a,
5,6-tetrahydro[1]benzothiepino[5,4-c)pyridazin-3(2H)-one ◎2-(5-methyl-2-thienyl)-4,4a,
5,6-tetrahydro[1]benzothiepino[5,4-c)pyridazin-3(2H)-one ◎2-(5-methyl-3-thienyl)-4,4a,
5,6-tetrahydro[1]benzothiepino[5,4-c)pyridazin-3(2H)-one ◎2-(5-methyl-2-thienyl)-5,6-dihydro-[1]benzothiepino[5,4 -c]
Pyridazin-3(2H)-one ◎2-(5-methyl-2-thienyl)-5,6-dihydro-[1]benzothiepino[5,4-c]
Pyridazin-3(2H)-one ◎2-(5-methyl-2-thienyl)-5,6-dihydro-[1]benzothiepino[5,4-c]
Pyridazin-3(2H)-one 7-oxide ◎2-(5-methyl-3-thienyl)-5,6-dihydro-[1]benzothiepino[5,4-c]
Pyridazin-3(2H)-one 7-oxide◎2-(5-methyl-2-thienyl)-4,4a,
5,6-tetrahydro[1]benzothiepino[5,4-c)pyridazin-3(2H)-one.
7,7-dioxide◎2-(5-methyl-3-thienyl)-4,4a,
5,6-tetrahydro[1]benzothiepino[5,4-c)pyridazin-3(2H)-one.
7,7-dioxide◎2-(5-methyl-2-thienyl)-5,6-dihydro-[1]benzothiepino[5,4-c]
Pyridazin-3(2H)-one 7,7-dioxide ◎2-(5-methyl-3-thienyl)-5,6-dihydro-[1]benzothiepino[5,4-c]
Pyridazin-3(2H)-one 7,7-dioxide The compound of the general formula () in the present invention is a new compound that has not been described in any literature, for example, the compound of the general formula (In the formula, each symbol has the same meaning as above.) Methyl iodide is added in acetone to the compound represented by the formula, and the mixture is kept at room temperature for 2 to 5 hours to obtain a quaternary ammonium compound. Add potassium cyanide or sodium cyanide to this in methanol or dimethylformamide,
React at 40-50℃ for 4-8 hours to obtain the general formula (In the formula, each symbol has the same meaning as above.) By adding acetic acid and concentrated hydrochloric acid and keeping it at 80 to 100°C for 8 to 10 hours, the general formula (In the formula, each symbol has the same meaning as above.) A compound is obtained. For reference, a representative example of compound (') is shown together with its physical constants. ◎5-oxo-2,3,4,5-tetrahydro-
[1] Benzothiepine-4-acetic acid, melting point 164~
167℃ ◎7-chloro-5-oxy-2,3,4,5-tetrahydro-[1]benzothiepine-4-acetic acid,
Melting point 203-205℃ ◎7-Fluoro-5-oxo-2,3,4,5-
Tetrahydro-[1]benzothiepine-4-acetic acid, melting point 191-193°C ◎7-Methyl-5-oxo-2,3,4,5-tetrahydro-[1]benzothiepine-4-acetic acid,
Melting point: 200-202°C [Actions and Effects of the Invention] In order to explain the usefulness of the compounds of the present invention, pharmacological actions will be shown below along with experimental methods. The compounds used in the test are as follows. Compound A: 2-(4-chlorophenyl)-5,6
-dihydro-[1]benzothiepino[5,4-c]
Pyridazin-3(2H)-one Compound B: 10-chloro-2-(4-chlorophenyl)-5,6-dihydro-[1]benzothiepino[5,4-c]pyridazin-3(2H)-one 7 −
Oxide Compound C: 2-(4-chlorophenyl)-5,6
-dihydro-[1]benzothiepino[5,4-c]
Pyridazin-3(2H)-one 7-oxide Compound D: 2-(4-chlorophenyl)-4,
4a,5,6-tetrahydro[1]benzothiepino[5,4-c)pyridazin-3(2H)-one.
7-oxide Compound E: 2(4-chlorophenyl)-10fluoro-5,6-dihydro-[1]benzothiepino[5,4-c]pyridazin-3(2H)-one Compound F: 2-(4-chlorophenyl) )-10-Fluoro-5,6-dihydro-[1]benzothiepino[5,4-c]pyridazin-3(2H)-one.
7-oxide Compound G: 2-(4-bromophenyl)-5,6
-dihydro-[1]benzothiepino[5,4-c]
Pyridazin-3(2H)-one 7-oxide Compound H: 2-(4-bromophenyl)4,
4a,5,6-tetrahydro[1]benzothiepino[5,4-c)pyridazin-3(2H)-one.
7-oxide Compound I: 10-fluoro-2-(4-fluorophenyl)-5,6-dihydro-[1]benzothiepino[5,4-c]pyridazin-3(2H)-one Compound J: 8- Chloro-2-(4-chlorophenyl)-5,6-dihydro-[1]benzothiepino[5,4-c]pyridazin-3(2H)-one 7-
Oxide experiment example 1 Displacement ability for benzodiazepine receptor Specific benzodiazepine receptor binding strength test was carried out in Life Science Vol. 20,
It was carried out according to the method described on page 2101 (1977). Crude synaptosome fraction was isolated from the cerebral cortex of 9-10 week old Wistar male rats, and 120mM
Contains sodium chloride and 5mM potassium chloride
It was suspended in 50mM Tris-HCl buffer (PH7.4) and used in the experiment. Next, several concentrations of the test compound and tritiated diazepam (final concentration 2 nM) were added to the synaptosome suspension and allowed to react at 0°C for 20 minutes. Thereafter, this suspension was filtered through a Whatman GF/B glass fiber filter, the filter was washed with the above buffer solution, and the radioactivity remaining on the filter was measured using a liquid scintillation counter. The amount of specific binding was determined by subtracting the amount of binding obtained in the presence of 10 -6 M non-radioactive diazepam from the total amount of binding. The affinity of a test compound for accepting benzodiazepines is assessed by its ability to displace tritiated diazepam from its binding site and is expressed as a Ki value. Table 1 shows the test results. Experimental example 2 Anti-bicuculline effect Life Science Vol. 21,
An anti-bicuculline effect test was conducted according to the method described on page 1779 (1977). Male ddY mice weighing 20 to 28 g were used in groups of 7 to 14 mice. One hour after oral administration of the test compound, 0.6 mg/Kg of (+) bicuculline was administered intravenously, and the occurrence of tonic extension convulsion within 5 minutes was examined to determine the 50% effective concentration (ED 50 value). Ta. Table 1 shows the test results.
【表】
実験例 3
抗不安作用
食餌制限によつて自由摂取時の約80%の体重に
維持した一群8匹の雄性ラツトをスキナー箱
(Skinner−box)内(側面にレバー、床にグリツ
ドが備えられている。)に入れ、レバー押しによ
るミルク取りの訓練を行い、十分な訓練によつて
最終的にレバーを20回押すことにより、1回だけ
0.1mlのミルクを獲得できる(定率強化スケジユ
ール、FR20)まで訓練した。次に、10分間の
FR20によるミルク取りを行わせた(安全期)後、
コンフリクトスケジユールでは5分間高周波の警
告音を与え(警告期)、この警告期に動物がレバ
ーを1回押すとその度にミルクを得られるが、そ
の報酬と同時にクリツドを介して0.3秒間のfoot
shock(AC100V、0.4〜0.8mA)を与えた。安全
期と警告期の反復訓練によつて安全期にのみ安定
した連続レバー押し反応を示し、警告期にはほと
んどレバー押し反応を示さず被シヨツク数が10以
下の動物を試験に供した。
試験化合物の経口投与30分後から安全期(10分
間)と警告期(5分間)を交互に4回くり返し、
安全期レバー押し数(計40分間)および警告期被
シヨツク数(百計20分間)を測定し、対照群に比
較して警告期被シヨツク数の有意な増加が認めら
れる投与量を最小有効量(MED、mg/Kg)とし
て求めた。結果を第2表に示す。
実験例 4
筋弛緩作用
一群10匹の雄性マウスに試験化合物を経口投与
し、1時間後に毎分11回の速さで回転する直径
2.8cmの回転棒にのせ、1分以内に落下する動物
の匹数を数えた。50%の動物を落下させる試験化
合物の投与量を50%有効投与量(ED50、mg/Kg)
としてプロビツト法により求めた。結果は第2表
に示す。
実験例 5
麻酔増強作用
26℃の恒温室内に入れておいた一群14匹の雄性
マウスに試験化合物を経口投与し、1時間後にヘ
キソバルビタール40mg/Kgを腹腔内投与した。ヘ
キソバルビタール投与15分および30分後に正向反
射(righting reflex)の消失を試験した。50%の
動物において3秒以上にわたる正向反射を消失さ
せる試験化合物の投与量を50%有効投与量
(ED50、mg/Kg)としてプロビツト法により求め
た。結果は第2表に示す。
実験例 6
アルコール脱強作用
26℃のの恒温室内に入れておいた一群14匹の雄
性マウスに試験化合物を経口投与し、1時間後に
30%エタノール0.1ml/10gを腹腔内投与した。エ
タノール投与15分および30分後に正向反射の消失
を試験した。50%の動物において3秒以上にわた
り正向反射を消失させる試験化合物の投与量を50
%有効投与量(ED50、mg/Kg)としてプロビツ
ト法により求めた。結果は第2表に示す。[Table] Experimental Example 3 Anxiolytic Effect A group of eight male rats, whose body weight was maintained at approximately 80% of their free intake through dietary restriction, were placed in a Skinner box (with a lever on the side and a grid on the floor). ), and trained to take out milk by pressing the lever, and with sufficient training, finally by pressing the lever 20 times, the milk was removed only once.
The animals were trained until they could obtain 0.1 ml of milk (constant rate reinforcement schedule, FR20). Then, for 10 minutes
After milk was extracted using FR20 (safety period),
In the conflict schedule, a high-frequency warning sound is given for 5 minutes (warning period), and each time the animal presses the lever once during this warning period, it receives milk, but at the same time, a 0.3-second foot is given through the clit as a reward.
A shock (AC100V, 0.4-0.8mA) was applied. Through repeated training in the safety period and warning period, animals that exhibited stable continuous lever pressing responses only during the safety period, showed almost no lever pressing responses during the warning period, and received fewer than 10 shots were subjected to the test. 30 minutes after oral administration of the test compound, a safety period (10 minutes) and a warning period (5 minutes) were repeated four times alternately.
The number of lever presses during the safety period (total of 40 minutes) and the number of shots taken during the warning period (100 minutes total) were measured, and the dose at which a significant increase in the number of shots taken during the warning period was observed compared to the control group was determined as the minimum effective dose. (MED, mg/Kg). The results are shown in Table 2. Experimental Example 4 Muscle Relaxation Effect A test compound was orally administered to a group of 10 male mice, and after 1 hour, the diameter rotated at a speed of 11 times per minute.
The animals were placed on a 2.8 cm rotating rod and the number of animals that fell within 1 minute was counted. The dose of the test compound that causes 50% of the animals to fall is the 50% effective dose ( ED50 , mg/Kg)
was calculated using the probit method. The results are shown in Table 2. Experimental Example 5 Anesthesia Enhancement Effect The test compound was orally administered to a group of 14 male mice kept in a constant temperature room at 26°C, and 1 hour later, 40 mg/Kg of hexobarbital was administered intraperitoneally. Loss of righting reflex was tested 15 and 30 minutes after hexobarbital administration. The dose of the test compound that abolished the righting reflex for 3 seconds or more in 50% of the animals was determined by the probit method as the 50% effective dose (ED 50 , mg/Kg). The results are shown in Table 2. Experimental example 6 Alcohol detonic effect A test compound was orally administered to a group of 14 male mice kept in a constant temperature room at 26°C, and 1 hour later
0.1 ml/10 g of 30% ethanol was administered intraperitoneally. The loss of righting reflex was tested 15 and 30 minutes after ethanol administration. A dose of test compound that abolishes the righting reflex for more than 3 seconds in 50% of animals is
The % effective dose (ED 50 , mg/Kg) was determined by the probit method. The results are shown in Table 2.
【表】
本発明化合物をラツトに投与したところ、300
mg/Kg腹腔内投与および1000mg/Kg経口投与にお
いても死亡例はみられなかつた。
上記した実験を含む種々の薬理実験から、本発
明の一般式()の化合物はベンゾジアゼピン受
容体に対して高い親和性を示し、ビククリン、ペ
ンチレンテトラゾールなどの化学的痙攣誘発剤に
対する拮抗作用を有し、また、ラツトにおける抗
コンフリクト試験において強い抗不安作用を示す
一方、筋弛緩作用、麻酔増強作用、アルコール増
強作用が弱く、かつ毒性も低いことから、本発明
化合物は安全性が高く、しかも選択的な抗不安薬
として有用であることが明らかになつた。本発明
化合物の有用な対象疾病病名としては、たとえば
自律神経失調症、神経性嘔吐症、神経性皮膚炎、
神経性狭心症、神経性呼吸困難症などあるいは各
種疾患により誘発される不安・緊張などの心身
症、不安神経症が挙げられ、これら疾病の予防・
改善または治療に用いることができる。また、ジ
アゼパムなどの既存抗不安薬の過量投与あるいは
中毒に対する中和剤としても有用である。
さらに、本発明のある種の群の化合物は白血球
貧食能亢進作用、マクロフアージの貧食能亢進作
用および感染防御作用などの薬理作用を有し、生
体防御能亢進剤として有用である。これら作用は
次の方法によつて確認することができる。
実験例 7
白血球の貧食能に対する作用
シユトツセル(Stossel)らの方法〔ジヤーナ
ル・オブ・クリニカル・インベステイゲーシヨン
(Journal of Clinical Investigation)第51巻、
615頁、1972年〕に準じて行なつた。
ICRマウス(体重30〜35g)にグリコーゲンを
腹腔内投与し、3時間後に腹水白血球を採取し、
5×106個/mlの白血球懸濁液を調製した。この
懸濁液200μに試験化合物を加え、さらに100μ
のマウス血清および100μのイースト死菌
(1×108個/ml)を加え、37℃で20分間反応させ
た。ついで反応液中の約200個の白血球を顕微鏡
(倍率400倍)下で観察し、1個以上のイースト死
菌を貧食した白血球数を計数した。対照の白血球
の貧食率に対し、化合物0.1μM添加時の相対的割
合を求めた。
実験例 8
マクロフアージの貧食能に対する作用
カゼイン・ナトリウムをラツト腹腔内に投与
し、3〜4日後に腹腔内からマクロフアージを採
取した。貧食能を実験例7と同様に0.1μM添加時
の相対的割合を求た。
実験例 9
感染防御作用
5週令の雄性ICRマウス(体重23〜27g)にシ
クロホスフアマイド200mg/Kgを腹腔内投与し、
4日後にエシユリシア・コリ(E.coli)0−111
株1×10-8CFUをマウスの皮下に接種した(コ
ントロール群)。同様に薬物投与群はシクロホス
フアマイド投与翌日より3日間、3mg/Kgを経口
投与した。E.coli接種7日後のコントロール群に
対する薬物投与群の生存率を比較した。
本発明化合物を医薬として用いる場合には、製
薬上許容される適宜の賦形剤、担体、希釈剤など
の添加剤と混合し、錠剤、カプセル剤、顆粒、シ
ロツプ剤、注射剤、坐剤または散剤などの形態で
投与できる。投与量は、たとえば経口投与の場
合、通常成人1日当り5〜500mg程度であり、こ
れを1回または数回に分けて投与することができ
る。
製剤処方例
本発明の化合物()10mgを含有する錠剤は次
の処方により調製することができる。
化合物() 10.0mg
乳 糖 58.5mg
トウモロコシデンプン 25.0mg
結晶セルロース 20.0mg
ポリビニルピロリドンK−30 2.0mg
タルク 4.0mg
ステアリン酸マグネシウム 0.5mg
120.0mg
化合物()をアトマイザーにより粉砕し、平
均粒子径10μ以下の微粉とする。化合物()、
乳糖、トウモロコシデンプンおよび結晶セルロー
スを練合機中で十分に混合したのち、ポリビニル
ピロリドン糊液を加えて練合する。練合物を200
メツシユの篩を通して造粒し、50℃の熱風乾燥機
中で水分3〜4%となるまで乾燥し、24メツシユ
の篩を通したのち、タルクおよびステアリン酸マ
グネシウムをを混合し、ロータリー式打錠機によ
り、直径8mmの平面杵を用いて打錠する。
(実施例)
以下、本発明を実施例により具体的に説明する
が、本発明はこれらにより何ら限定されるもので
はない。
実施例 1
5−オキソ−2,3,4,5−テトラヒドロ−
〔1〕ベンゾチエピン−4−酢酸4gをエタノール
50mlに溶解し、フエニルヒドラジン2.0mlを加え、
12時間加熱還流後、溶媒を留去し、酢酸20mlを加
え2時間加熱還流する。溶媒を留去し、水を加え
た後、酢酸エチルで抽出する。水洗後、無水硫酸
マグネシウムにて乾燥し、溶媒を留去する。粗生
成物をカラムクロマトグラフイーにて精製後、得
られた結晶をエタノールから再結晶すると、融点
138〜140℃の、2−フエニル−4,4a,5,6
−テトラヒドロ〔1〕ベンゾチエピノ〔5,4ー
c)ピリダジンー3(2H)−オン2.3gが得られる。
実施例 2
実施例1で用いたフエニルヒドラジンの代わり
に、ヒドラジンを用いて同様の方法により反応お
よび処理を行なうと、融点198〜200℃の4,4a,
5,6−テトラヒドロ〔1〕ベンゾチエピノ
〔5,4ーc)ピリダジンー3(2H)−オンが得ら
れる。
実施例 3
実施例1で用いたフエニルヒドラジンの代わり
に、4−クロロフエニルヒドラジンを用いて同様
の方法により反応および処理を行なうと、融点
140〜142℃の2−(4−クロロフエニル)−4,
4a,5,6−テトラヒドロ〔1〕ベンゾチエピ
ノ〔5,4ーc)ピリダジンー3(2H)−オンが
得られる。
実施例 4
5−オキソ−2,3,4,5−テトラヒドロ−
〔1〕ベンゾチエピン−4−酢酸4gをエタノール
100mlに溶解し、4−メトキシフエニルヒドラジ
ン・塩酸塩3.5gおよ酢酸ナトリウム1.8gを加え、
12時間加熱還流後、溶媒を留去し、さらに酢酸20
mlを加え、2時間加熱還流する。ついで、溶媒を
留去し、水を加え酢酸エチルで抽出後、水洗し、
無水硫酸マグネシウムにて乾燥後、溶媒を留去す
る。得られた粗生成物をカラムクロマトグラフイ
ーにて精製し、さらにエタノールから再結晶する
と、融点143〜145℃の2−(4−メトキシフエニ
ル)−4,4a,5,6−テトラヒドロ〔1〕ベン
ゾチエピノ〔5,4ーc)ピリダジンー3(2H)
−オン1.9gが得られる。
実施例 5
実施例4で用いた4−メトキシフエニルヒドラ
ジン・塩酸塩の代わりに、、4−メチルフエニル
ヒドラジン・塩酸塩を用いて同様の方法により反
応および処理を行なうと、融点128〜130℃の2−
(4−メチルフエニル)−4,4a,5,6−テト
ラヒドロ〔1〕ベンゾチエピノ〔5,4ーc)ピ
リダジンー3(2H)−オンが得られる。
実施例 6
実施例4で用いた4−メトキシフエニルヒドラ
ジン・塩酸塩の代わりに、3−クロロフエニルヒ
ドラジン・塩酸塩を用いて同様の方法により反応
および処理を行なうと、融点122〜123℃の2−
(3−クロロフエニル)−4,4a,5,6−テト
ラヒドロ〔1〕ベンゾチエピノ〔5,4ーc)ピ
リダジンー3(2H)−オンが得られる。
実施例 7
実施例4で用いた4−メトキシフエニルヒドラ
ジン・塩酸塩の代わりに、4−ブロモフエニルヒ
ドラジン・塩酸塩を用いて同様の方法により反応
およ処理を行なうと、融点135〜137℃の2−(4
−ブロモフエニル)−4,4a,5,6−テトラヒ
ドロ〔1〕ベンゾチエピノ〔5,4ーc)ピリダ
ジンー3(2H)−オンが得られる。
実施例 8
実施例4で用いた4−メトキシフエニルヒドラ
ジン・塩酸塩の代わりに、2−クロロフエニルヒ
ドラジン・塩酸塩を用いて同様の方法により反応
および処理を行なうと、融点148〜150℃の2−
(2−クロロフエニル)−4,4a,5,6−テト
ラヒドロ〔1〕ベンゾチエピノ〔5,4ーc)ピ
リダジンー3(2H)−オンが得られる。
実施例 9
実施例4で用いた5−オキソ−2,3,4,5
−テトラヒドロ−〔1〕ベンゾチエピン−4−酢
酸の代わりに、7−クロロ−5−オキソ−2,
3,4,5−テトラヒドロ−〔1〕ベンゾチエピ
ン−4−酢酸を用いて同様の方法により反応およ
び処理を行なうと、融点159〜161℃の10−クロロ
−2−(4−メトキシフエニル)−4,4a,5,
6−テトラヒドロ〔1〕ベンゾチエピノ〔5,4
ーc)ピリダジンー3(2H)−オンが得られる。
実施例 10
実施例4で用いた5−オキソ−2,3,4,5
−テトラヒドロ−〔1〕ベンゾチエピン−4−酢
酸の代わりに、7−クロロ−5−オキソ−2,
3,4,5−テトラヒドロ−〔1〕ベンゾチエピ
ン−4−酢酸を用い、さらに4−メトキシフエニ
ルヒドラジン・塩酸塩の代わりに、4−クロロフ
エニルヒドラジン・塩塩酸をを用いて同様の方法
により反応および処理を行なうと、融点141〜143
℃の10−クロロ−2−(4−クロロフエニル)−
4,4a,5,6−テトラヒドロ〔1〕ベンゾチ
エピノ〔5,4ーc)ピリダジンー3(2H)−オ
ンが得られる。
実施例 11
実施例10で合成した10−クロロ−2−(4−ク
ロロフエニル)−4,4a,5,6−テトラヒドロ
〔1〕ベンゾチエピノ〔5,4ーc)ピリダジン
ー3(2H)−オン3.0gを酢酸90mlに溶解し、内温
40〜50℃にて臭素0.4mlを加え、さらに同温にて
30分攪拌後、減圧下に濃縮し水を加える。析出し
た結晶を濾取し、クロロホルムに溶解し、水洗後
無水硫酸マグネシウムにて乾燥し、溶媒を留去す
る。得られた粗生成物をカラムクロマトグラフイ
ーにて精製後、さらにクロロホルム−メタノール
から再結晶すると、融点215〜217℃の10−クロロ
−2−(4−クロロフエニル)−5,6−ジヒドロ
−〔1〕ベンゾチエピノ〔5,4−c〕ピリダジ
ン−3(2H)−オン2.4gが得られる。
実施例 12
実施例11で用いた10−クロロ−2−(4−クロ
ロフエニル)−4,4a,5,6−テトラヒドロ
〔1〕ベンゾチエピノ〔5,4ーc)ピリダジン
ー3(2H)−オンの代わりに、2−(4−クロロフ
エニル)−4,4a,5,6−テトラヒドロ〔1〕
ベンゾチエピノ〔5,4ーc)ピリダジンー3
(2H)−オンを用いて同様の方法により反応およ
び処理を行なうと、融点185〜186℃の2−(4−
クロロフエニル)−5,6−ジヒドロ−〔1〕ベン
ゾチエピノ〔5,4−c〕ピリダジン−3(2H)
−オンが得られる。
実施例 13
実施例11で合成した10−クロロ−2−(4−ク
ロロフエニル)−5,6−ジヒドロ−〔1〕ベンゾ
チエピノ〔5,4−c〕ピリダジン−3(2H)−
オン2.4gにアセトン300mlおよび水25mlを水、攪
拌下、亜臭素酸ナトリウム・3水和物2.8gを加え
る。室温にて18時間攪拌後、減圧下に濃縮し、水
を加え、析出した結晶濾取し、ジメチルホルムア
ミド−水から再結晶すると、融点239〜241℃(分
解)の10−クロロ−2−(4−クロロフエニル)−
5,6−ジヒドロ−〔1〕ベンゾチエピノ〔5,
4−c〕ピリダジン−3(2H)−オン・7−オキ
シド1.0gが得られる。
実施例 14
実施例13で用いた10−クロロ−2−(4−クロ
ロフエニル)−5,6−ジヒドロ−〔1〕ベンゾチ
エピノ〔5,4−c〕ピリダジン−3(2H)−オ
ンの代わりに、実施例12で合成した2−(4−ク
ロロフエニル)−5,6−ジヒドロ−〔1〕ベンゾ
チエピノ〔5,4−c〕ピリダジン−3(2H)−
オン用いて同様の方法により反応および処理を行
なうと、融点233〜234℃(分解)の2−(4−ク
ロロフエニル)−5,6−ジヒドロ−〔1〕ベンゾ
チエピノ〔5,4−c〕ピリダジン−3(2H)−
オン・7−オキシドが得られる。
実施例 15
実施例13で用いた10−クロロ−2−(4−クロ
ロフエニル)−5,6−ジヒドロ−〔1〕ベンゾチ
エピノ〔5,4−c〕ピリダジン−3(2H)−オ
ンの代わりに、実施例4で合成した2−(4−メ
トキシフエニル)−4,4a,5,6−テトラヒド
ロ〔1〕ベンゾチエピノ〔5,4ーc)ピリダジ
ンー3(2H)−オンを用いて同様の方法により反
応および処理を行なうと、融点203〜205℃(分
解)の2−(4−メトキシフエニル)−4,4a,
5,6−テトラヒドロ〔1〕ベンゾチエピノ
〔5,4ーc)ピリダジンー3(2H)−オン・7−
オキシドが得られる。
実施例 16
実施例13で用いた10−クロロ−2−(4−クロ
ロフエニル)−5,6−ジヒドロ−〔1〕ベンゾチ
エピノ〔5,4−c〕ピリダジン−3(2H)−オ
ンの代わりに、実施例1で合成した2−フエニル
−4,4a,5,6−テトラヒドロ〔1〕ベンゾ
チエピノ〔5,4ーc)ピリダジンー3(2H)−
オンを用いて同様の方法により反応および処理を
行なうと、融点187〜190℃(分解)の2−フエニ
ル−4,4a,5,6−テトラヒドロ〔1〕ベン
ゾチエピノ〔5,4ーc)ピリダジンー3(2H)
−オン・7−オキシドが得られる。
実施例 17
実施例13で用いた10−クロロ−2−(4−クロ
ロフエニル)−5,6−ジヒドロ−〔1〕ベンゾチ
エピノ〔5,4−c〕ピリダジン−3(2H)−オ
ンの代わりに、実施例3で合成した2−(4−ク
ロロフエニル)−4,4a,5,6−テトラヒドロ
〔1〕ベンゾチエピノ〔5,4ーc)ピリダジン
ー3(2H)−オンを用いて同様の方法により反応
および処理を行なうと、融点217〜220℃(分解)
の2−(4−クロロフエニル)−4,4a,5,6
−テトラヒドロ〔1〕ベンゾチエピノ〔5,4ー
c)ピリダジンー3(2H)−オン・7−オキシド
が得られる。
実施例 18
実施例17で得られた2−(4−クロロフエニル)
−4,4a,5,6−テトラヒドロ〔1〕ベンゾ
チエピノ〔5,4ーc)ピリダジンー3(2H)−
オン・7−オキシドをヘキサン−酢酸エチル
(3:1)の混合溶媒を溶出液としてシリカゲル
カラムクロマトグラフイーにより分離、精製し、
第1溶出部から得られる結晶をイソプロピルアル
コールから再結晶すると、融点247〜248℃(分
解)の(4aR*,7S*)−2−(4−クロロフエニ
ル)−4,4a,5,6−テトラヒドロ−〔1〕ベ
ンゾチエピノ〔5,4ーc)ピリダジンー3
(2H)−オン・7−オキシドが得られる。また、
第2溶出部から得られる結晶をイソプロピルアル
コールから再結晶すると、融点190〜191℃(分
解)の(4aR*,7R*)−2−(4−クロロフエニ
ル)−4,4a,5,6−テトラヒドロ〔1〕ベン
ゾチエピノ〔5,4ーc)ピリダジンー3(2H)
−オン・7−オキシドが得られる。
実施例 19
実施例13で用いた10−クロロ−2−(4−クロ
ロフエニル)−5,6−ジヒドロ−〔1〕ベンゾチ
エピノ〔5,4−c〕ピリダジン−3(2H)−オ
ンの代わりに、実施例10で合成した10−クロロ−
2−(4−クロロフエニル)−4,4a,5,6−
テトラヒドロ〔1〕ベンゾチエピノ〔5,4ー
c)ピリダジンー3(2H)−オンを用いて同様の
方法により反応および処理を行なうと、融点198
〜202℃(分解)の10−クロロ−2−(4−クロロ
フエニル)−4,4a,5,6−テトラヒドロ
〔1〕ベンゾチエピノ〔5,4ーc)ピリダジン
ー3(2H)−オン・7−オキシドが得られる。
実施例 20
実施例14で合成した2−(4−クロロフエニル)
−5,6−ジヒドロ−〔1〕ベンゾチエピノ〔5,
4−c〕ピリダジン−3(2H)−オン・7−オキ
シド14gを酢酸200mlに溶解し、攪拌下、室温に
て過酸化水素15mlを加える。さらに50〜55℃にて
2時間攪拌後、反応液を水1にあけ、析出した
結晶を濾取する。得られた粗生成物をシリカゲル
カラムクロマトグラフイーにて精製し、クロロホ
ルム−メタノールから再結晶すると、融点310℃
以上の2−(4−クロロフエニル)−5,6−ジヒ
ドロ−〔1〕ベンゾチエピノ〔5,4−c〕ピリ
ダジン−3(2H)−オン・7,7−オキシド9.8g
が得られる。
実施例 21
実施例1で用いた5−オキソー2,3,4,5
−テトラヒドロ−〔1〕ベンゾチエピン−4−酢
酸の代わりに、7−フルオロ−5−オキソ−2,
3,4,5−テトラヒドロ−〔1〕ベンゾチエピ
ン−4−酢酸を用い、さらにフエニルヒドラジン
の代わりに、4−クロロフエニルヒドラジンをを
用いて同様の方法により反応および処理を行なう
と、融点141〜142℃の2−(4−クロロフエニル)
−10−フルオロ−4,4a,5,6−テトラヒド
ロ〔1〕ベンゾチエピノ〔5,4ーc)ピリダジ
ンー3(2H)−オンが得られる。
実施例 22
実施例11で用いた10−クロロ−2−(4−クロ
ロフエニル)−4,4a,5,6−テトラヒドロ
〔1〕ベンゾチエピノ〔5,4ーc)ピリダジン
ー3(2H)−オンの代わりに、2−(4−クロロフ
エニル)−10−フルオロ−4,4a,5,6−テト
ラヒドロ〔1〕ベンゾチエピノ〔5,4ーc)ピ
リダジンー3(2H)−オンを用いて同様の方法に
より反応および処理を行なうと、融点160〜162℃
の2−(4−クロロフエニル)−10−フルオロ−
5,6−ジヒドロ−〔1〕ベンゾチエピノ〔5,
4−c〕ピリダジン−3(2H)−オンが得られる。
実施例 23
実施例22で合成した2−(4−クロロフエニル)
−10−フルオロ−5,6−ジヒドロ−〔1〕ベン
ゾチエピノ〔5,4−c〕ピリダジン−3(2H)
−オン1.8g酢酸20mlに溶解し、室温攪拌下、35%
過酸化水素水1.3mlを加える。さらに同温にて5
時間攪拌後、水を加え、析出した結晶を濾取し、
ジメチルホルムアミド−水から再結晶すると、融
点233〜235℃(分解)の2−(4−クロロフエニ
ル)−10−フルオロ−5,6−ジヒドロ−〔1〕ベ
ンゾチエピノ〔5,4−c〕ピリダジン−3
(2H)−オン・7−オキシド1.3gが得られる。
実施例 24
9−クロロ−5−オキソ−2,3,4,5−テ
トラヒドロ−〔1〕ベンゾチエピン−4−酢酸8g
をブタノール100mlに溶解し、4−クロロフエニ
ルヒドラジン5gを加え、16時間加熱還流する。
溶媒を留去し、残査に酢酸20mlを加え、5時間加
熱還流する。溶媒を留去後、残査に水を加え、酢
酸エチルで抽出する。炭酸水素ナトリウム水溶液
で洗浄後、無水硫酸マグネシウムで乾燥し、溶媒
を留去する。残査をシリカゲルカラムクロマトグ
ラフイーにより精製すると淡褐色油状物質3gを
得る。
このものを酢酸30mlに溶解し、室温下臭素0.41
mlを加え、さらに内温40〜50℃で1時間攪拌す
る。反応終了後、溶媒を減圧にて留去し、残査を
シリカゲルカラムクロマトグラフイーにて精製
後、エタノールから再結晶すると、融点166〜16
℃の8−クロロ−2−(4−クロロフエニル)−
5,6−ジヒドロ−〔1〕ベンゾチエピノ〔5,
4−c〕ピリダジン−3(2H)−オンが得られる。
実施例 25
実施例24で合成した8−クロロ−2−(4−ク
ロロフエニル)−5,6−ジヒドロ−〔1〕ベンゾ
チエピノ〔5,4−c〕ピリダジン−3(2H)−
オン0.9gを酢酸20mlに溶解し、室温にて攪拌下、
35%過酸化水素水0.6mlを加え、さらに同温にて
18時間攪拌する。水を加え、析出する結晶を濾取
し、さらにエタノールで洗浄をくり返すと、融点
217〜219℃(分解)の8−クロロ−2−(4−ク
ロロフエニル)−5,6−ジヒドロ−〔1〕ベンゾ
チエピノ〔5,4−c〕ピリダジン−3(2H)−
オン・7−オキシド0.7gが得られる。
実施例 26
4,4a,5,6−テトラヒドロ〔1〕ベンゾ
チエピノ〔5,4ーc)ピリダジンー3(2H)−
オン92gを酢酸920mlに加え、50〜60℃で臭素64g
滴下し、同温に1時間保つ。大量水に注ぎ込み、
生じた結晶を濾取する。塩水、次いでエタノール
で洗浄後乾燥すると、−5,6−ジヒドロ−〔1〕
ベンゾチエピノ〔5,4−c〕ピリダジン−3
(2H)−オン85g得る。融点31〜313℃(分解)。
実施例 27
実施例26で得た化合物5gジメチルホルムアミ
ド50mlに溶解し、60℃水素化ナトリウム1.0gを添
加後、30分間攪拌する。35〜40℃でヨウ化メチル
5gを滴下し、同温に1時間保つ。反応液を水に
注ぎ、酢酸エチルにて抽出後、水洗し、硫酸マグ
ネシウムで乾燥する。濃縮して得た結晶を濾取
し、エタノールから再結晶すると、2−メチル−
5,6−ジヒドロ−〔1〕ベンゾチエピノ〔5,
4−c〕ピリダジン−3(2H)−オン2.8gを得る。
融点139〜140℃。
実施例 28
実施例27のヨウ化メチルの代わりにベンジルク
ロライドを用いると、2−ベンジル−5,6−ジ
ヒドロ−〔1〕ベンゾチエピノ〔5,4−c〕ピ
リダジン−3(2H)−オンが得られる。融点190〜
192℃。
実施例 29
実施例27ヨウ化メチルの代わりに4−クロロベ
ンジルクロライドを用いると、2−(4−クロロ
ベンジル)−5,6−ジヒドロ−〔1〕ベンゾチエ
ピノ〔5,4−c〕ピリダジン−3(2H)−オン
が得られる。融点224〜225℃。
実施例 30
実施例27のヨウ化メチルの代わりに臭化ブチル
用いると、2−ブチル−5,6−ジヒドロ−〔1〕
ベンゾチエピノ〔5,4−c〕ピリダジン−3
(2H)−オンが得られる。融点108〜110℃。
実施例 31
実施例28で得た化合物5.8g酢酸200mlに溶かし、
35%過酸化水素5gを添加し、室温に5時間保つ。
氷水に注ぎ込み、生じた結晶を濾取し、60%酢酸
水溶液から再結晶すると、2−(4−クロロベン
ジル)−5,6−ジヒドロ−〔1〕ベンゾチエピノ
〔5,4−c〕ピリダジン−3(2H)−オン・7−
オキシド4.2gが得られる。融点207〜209℃(分
解)。
実施例 32
実施例31で得た化合物3.4g酢酸200mlに加え、
45〜50℃にて加熱溶解する。35%過酸化水素水
20gを添加し、同温に3時間保つ。大量の水に注
ぎ込み、生じた結晶を濾取し、水洗後、60%酢酸
水溶液から再結晶すると、2−(4−クロロベン
ジル)−5,6−ジヒドロ−〔1〕ベンゾチエピノ
〔5,4−c〕ピリダジン−3(2H)−オン・7,
7−オキシド2.6g得る。融点238〜239℃(分解)。
上記実施例と同様にして以下の化合物が得られ
る。
実施例 33
2−(4−ブロモフエニル)−5,6−ジヒドロ
−〔1〕ベンゾチエピノ〔5,4−c〕ピリダジ
ン−3(2H)−オン・7−オキシド、融点227℃
(分解)。
実施例 34
10−メチル−4,4a,5,6−テトラヒドロ
〔1〕ベンゾチエピノ〔5,4ーc)ピリダジン
ー3(2H)−オン、融点185〜187℃
実施例 35
2−(4−クロロフエニル)−10−メチル−4,
4a,5,6−テトラヒドロ〔1〕ベンゾチエピ
ノ〔5,4ーc)ピリダジンー3(2H)−オン、
融点151〜153℃
実施例 36
10−メチル−2−(4−メチルフエニル)−4,
4a,5,6−テトラヒドロ〔1〕ベンゾチエピ
ノ〔5,4ーc)ピリダジンー3(2H)−オン、
融点164〜166℃
実施例 37
2−(4−ブロモフエニル)−4,4a,5,6
−テトラヒドロ〔1〕ベンゾチエピノ〔5,4ー
c)ピリダジンー3(2H)−オン・7−オキシド、
融点227〜229℃(分解)
実施例 38
2−(4−ブロモフエニル)−5,6−ジヒドロ
−〔1〕ベンゾチエピノ〔5,4−c〕ピリダジ
ン−3(2H)−オン、融点199〜201℃
実施例 39
2−(4−クロロフエニル)−10−メチル−5,
6−ジヒドロ−〔1〕ベンゾチエピノ〔5,4−
c〕ピリダジン−3(2H)−オン、融点182〜184
℃
実施例 40
2−(4−クロロフエニル)−10−メチル−5,
6−ジヒドロ−〔1〕ベンゾチエピノ〔5,4−
c〕ピリダジン−3(2H)−オン・7−オキシド、
融点237〜239℃(分解)
実施例 41
10−フルオロ−2−(4−フルオロフエニル)−
4,4a,5,6−テトラヒドロ〔1〕ベンゾチ
エピノ〔5,4ーc)ピリダジンー3(2H)−オ
ン、融点175〜177℃
実施例 42
10−フルオロ−2−(4−フルオロフエニル)−
5,6−ジヒドロ−〔1〕ベンゾチエピノ〔5,
4−c〕ピリダジン−3(2H)−オン、融点169〜
171℃
実施例 43
10−フルオロ−2−(4−フルオロフエニル)−
5,6−ジヒドロ−〔1〕ベンゾチエピノ〔5,
4−c〕ピリダジン−3(2H)−オン・7−オキ
シド、融点227〜229℃(分解)
実施例 44
2−(4−フルオロフエニル)−4,4a,5,
6−テトラヒドロ〔1〕ベンゾチエピノ〔5,4
ーc)ピリダジンー3(2H)−オン、融点146〜
147℃
実施例 45
2−(4−フルオロフエニル)−5,6−ジヒド
ロ−〔1〕ベンゾチエピノ〔5,4−c〕ピリダ
ジン−3(2H)−オン、融点163〜165℃
実施例 46
2−(4−フルオロフエニル)−5,6−ジヒド
ロ−〔1〕ベンゾチエピノ〔5,4−c〕ピリダ
ジン−3(2H)−オン・7−オキシド、融点225〜
226℃(分解)
実施例 47
2−(3,4−ジクロロフエニル)−4,4a,
5,6−テトラヒドロ〔1〕ベンゾチエピノ
〔5,4ーc)ピリダジンー3(2H)−オン、融点
134〜136℃
実施例 48
10−フルオロ−2−(3,4−ジクロロフエニ
ル)−5,6−ジヒドロ−〔1〕ベンゾチエピノ
〔5,4−c〕ピリダジン−3(2H)−オン、融点
156〜157℃
実施例 49
10−フルオロ−2−(3−トリフルオロメチル
フエニル)−5,6−ジヒドロ−〔1〕ベンゾチエ
ピノ〔5,4−c〕ピリダジン−3(2H)−オ
ン・7−オキシド、融点203〜204℃(分解)
実施例 50
10−フルオロ−2−(3,4−ジクロロフエニ
ル)−5,6−ジヒドロ−〔1〕ベンゾチエピノ
〔5,4−c〕ピリダジン−3(2H)−オン、7,
7−ジオキシド、融点253〜255℃(分解)
実施例 51
8−クロロ−2−(4−クロロフエニル)−5,
6−ジヒドロ−〔1〕ベンゾチエピノ〔5,4−
c〕ピリダジン−3(2H)−オン・7,7−ジオ
キシド、融点219〜220℃(分解)
本発明を上述の明細書およびそれに包含される
実施例で十分に説明したが、これらは本発明の精
神と範囲に反することなく種々に変更、修飾する
ことができる。[Table] When the compound of the present invention was administered to rats, 300
No deaths were observed with mg/Kg intraperitoneal administration or 1000 mg/Kg oral administration. Various pharmacological experiments, including those described above, have shown that the compound of the general formula () of the present invention exhibits high affinity for benzodiazepine receptors and has an antagonistic effect on chemical convulsant inducers such as bicuculline and pentylenetetrazole. Furthermore, while it shows strong anxiolytic effects in anti-conflict tests in rats, it has weak muscle-relaxing, anesthetic-enhancing, and alcohol-enhancing effects, as well as low toxicity; therefore, the compounds of the present invention are highly safe and are highly selective. It has become clear that it is useful as an anti-anxiety drug. Examples of useful target diseases for the compounds of the present invention include autonomic nervous system imbalance, neurogenic emesis, neurodermatitis,
These include psychosomatic disorders such as angina pectoris, dyspnoea nervosa, anxiety and tension induced by various diseases, and anxiety neurosis.
It can be used for improvement or treatment. It is also useful as a neutralizer for overdosing or poisoning of existing anxiolytics such as diazepam. Furthermore, certain groups of compounds of the present invention have pharmacological effects such as leukocyte anemia-enhancing activity, macrophage anemia-enhancing activity, and infection defense activity, and are useful as biological defense enhancers. These effects can be confirmed by the following method. Experimental Example 7 Effect on leukocyte phagocytosis The method of Stossel et al. [Journal of Clinical Investigation, Vol. 51,
615, 1972]. Glycogen was intraperitoneally administered to ICR mice (body weight 30-35 g), and ascites leukocytes were collected 3 hours later.
A leukocyte suspension of 5×10 6 cells/ml was prepared. Add test compound to 200μ of this suspension and add 100μ
of mouse serum and 100 μ of killed yeast bacteria (1×10 8 cells/ml) were added, and the mixture was allowed to react at 37° C. for 20 minutes. Approximately 200 leukocytes in the reaction solution were then observed under a microscope (400x magnification), and the number of leukocytes that had phagocytosed one or more dead yeast bacteria was counted. The relative percentage of leukocyte phagocytosis when 0.1 μM of the compound was added was determined compared to the control leukocyte phagocytosis rate. Experimental Example 8 Effect of macrophages on poor phagocytosis Sodium caseinate was intraperitoneally administered to rats, and macrophages were collected intraperitoneally 3 to 4 days later. Similar to Experimental Example 7, the relative proportion of oligophagous ability was determined when 0.1 μM was added. Experimental Example 9 Infection protection effect Cyclophosphamide 200mg/Kg was administered intraperitoneally to 5-week-old male ICR mice (body weight 23-27g).
E.coli 0-111 after 4 days
Mice were subcutaneously inoculated with 1×10 −8 CFU of the strain (control group). Similarly, the drug administration group received 3 mg/Kg orally for 3 days starting from the day after administration of cyclophosphamide. Seven days after E. coli inoculation, the survival rate of the drug-administered group was compared with the control group. When the compound of the present invention is used as a medicine, it is mixed with appropriate pharmaceutically acceptable excipients, carriers, diluents, and other additives, and prepared into tablets, capsules, granules, syrups, injections, suppositories, or It can be administered in the form of a powder, etc. For example, in the case of oral administration, the dosage is usually about 5 to 500 mg per day for adults, and this can be administered once or in divided doses. Formulation Example Tablets containing 10 mg of the compound of the present invention can be prepared according to the following formulation. Compound () 10.0mg Lactose 58.5mg Corn starch 25.0mg Crystalline cellulose 20.0mg Polyvinylpyrrolidone K-30 2.0mg Talc 4.0mg Magnesium stearate 0.5mg 120.0mg Compound () was ground with an atomizer to form a fine powder with an average particle size of 10μ or less. shall be. Compound(),
After thoroughly mixing lactose, corn starch, and crystalline cellulose in a kneader, polyvinylpyrrolidone paste is added and kneaded. 200 kneaded mixture
Granulate through a mesh sieve, dry in a hot air dryer at 50°C until the moisture content is 3-4%, pass through a 24 mesh sieve, mix with talc and magnesium stearate, and rotary tablet. The tablets are compressed by a machine using a flat punch with a diameter of 8 mm. (Examples) Hereinafter, the present invention will be specifically explained with reference to Examples, but the present invention is not limited to these in any way. Example 1 5-oxo-2,3,4,5-tetrahydro-
[1] 4g of benzothiepine-4-acetic acid in ethanol
Dissolve in 50ml, add 2.0ml of phenylhydrazine,
After heating under reflux for 12 hours, the solvent was distilled off, 20 ml of acetic acid was added, and the mixture was heated under reflux for 2 hours. The solvent is distilled off, water is added, and the mixture is extracted with ethyl acetate. After washing with water, it is dried over anhydrous magnesium sulfate and the solvent is distilled off. After the crude product was purified by column chromatography, the resulting crystals were recrystallized from ethanol, and the melting point
2-phenyl-4,4a,5,6 at 138-140℃
2.3 g of -tetrahydro[1]benzothiepino[5,4-c)pyridazin-3(2H)-one are obtained. Example 2 When hydrazine was used in place of the phenylhydrazine used in Example 1 and the reaction and treatment were carried out in the same manner, 4,4a, with a melting point of 198-200°C, was obtained.
5,6-tetrahydro[1]benzothiepino[5,4-c)pyridazin-3(2H)-one is obtained. Example 3 When the reaction and treatment were carried out in the same manner using 4-chlorophenylhydrazine instead of the phenylhydrazine used in Example 1, the melting point
2-(4-chlorophenyl)-4 at 140-142℃,
4a,5,6-tetrahydro[1]benzothiepino[5,4-c)pyridazin-3(2H)-one is obtained. Example 4 5-oxo-2,3,4,5-tetrahydro-
[1] 4g of benzothiepine-4-acetic acid in ethanol
Dissolve in 100ml, add 3.5g of 4-methoxyphenylhydrazine hydrochloride and 1.8g of sodium acetate,
After heating under reflux for 12 hours, the solvent was distilled off, and acetic acid
ml and heated under reflux for 2 hours. Then, the solvent was distilled off, water was added, extracted with ethyl acetate, and washed with water.
After drying over anhydrous magnesium sulfate, the solvent was distilled off. The obtained crude product was purified by column chromatography and further recrystallized from ethanol to obtain 2-(4-methoxyphenyl)-4,4a,5,6-tetrahydro[1] with a melting point of 143-145°C. ]Benzothiepino[5,4-c)pyridazine-3(2H)
- 1.9 g of on is obtained. Example 5 When the reaction and treatment were carried out in the same manner using 4-methylphenylhydrazine hydrochloride instead of the 4-methoxyphenylhydrazine hydrochloride used in Example 4, the melting point was 128-130. 2-℃
(4-Methylphenyl)-4,4a,5,6-tetrahydro[1]benzothiepino[5,4-c)pyridazin-3(2H)-one is obtained. Example 6 When the reaction and treatment were carried out in the same manner using 3-chlorophenylhydrazine hydrochloride instead of the 4-methoxyphenylhydrazine hydrochloride used in Example 4, a reaction product with a melting point of 122 to 123°C was obtained. 2-
(3-chlorophenyl)-4,4a,5,6-tetrahydro[1]benzothiepino[5,4-c)pyridazin-3(2H)-one is obtained. Example 7 When the reaction and treatment were carried out in the same manner using 4-bromophenylhydrazine hydrochloride instead of the 4-methoxyphenylhydrazine hydrochloride used in Example 4, the melting point was 135 to 137. ℃ 2-(4
-bromophenyl)-4,4a,5,6-tetrahydro[1]benzothiepino[5,4-c)pyridazin-3(2H)-one is obtained. Example 8 When the reaction and treatment were carried out in the same manner using 2-chlorophenylhydrazine hydrochloride instead of the 4-methoxyphenylhydrazine hydrochloride used in Example 4, a reaction product with a melting point of 148 to 150°C was obtained. 2-
(2-chlorophenyl)-4,4a,5,6-tetrahydro[1]benzothiepino[5,4-c)pyridazin-3(2H)-one is obtained. Example 9 5-oxo-2,3,4,5 used in Example 4
-tetrahydro-[1]benzothiepine-4-acetic acid instead of 7-chloro-5-oxo-2,
A similar reaction and treatment using 3,4,5-tetrahydro-[1]benzothiepine-4-acetic acid yielded 10-chloro-2-(4-methoxyphenyl)- with a melting point of 159-161°C. 4,4a,5,
6-tetrahydro[1]benzothiepino[5,4
-c) Pyridazin-3(2H)-one is obtained. Example 10 5-oxo-2,3,4,5 used in Example 4
-tetrahydro-[1]benzothiepine-4-acetic acid instead of 7-chloro-5-oxo-2,
Reaction was carried out in the same manner using 3,4,5-tetrahydro-[1]benzothiepine-4-acetic acid and using 4-chlorophenylhydrazine hydrochloride instead of 4-methoxyphenylhydrazine hydrochloride. and with treatment, melting point 141-143
10-chloro-2-(4-chlorophenyl)- at °C
4,4a,5,6-tetrahydro[1]benzothiepino[5,4-c)pyridazin-3(2H)-one is obtained. Example 11 3.0 g of 10-chloro-2-(4-chlorophenyl)-4,4a,5,6-tetrahydro[1]benzothiepino[5,4-c)pyridazin-3(2H)-one synthesized in Example 10 Dissolve in 90ml of acetic acid and bring to internal temperature.
Add 0.4ml of bromine at 40-50℃, and then at the same temperature.
After stirring for 30 minutes, concentrate under reduced pressure and add water. The precipitated crystals are collected by filtration, dissolved in chloroform, washed with water, dried over anhydrous magnesium sulfate, and the solvent is distilled off. After the obtained crude product was purified by column chromatography and further recrystallized from chloroform-methanol, 10-chloro-2-(4-chlorophenyl)-5,6-dihydro-[ 1] 2.4 g of benzothiepino[5,4-c]pyridazin-3(2H)-one are obtained. Example 12 Substitute for 10-chloro-2-(4-chlorophenyl)-4,4a,5,6-tetrahydro[1]benzothiepino[5,4-c)pyridazin-3(2H)-one used in Example 11 2-(4-chlorophenyl)-4,4a,5,6-tetrahydro[1]
Benzothiepino[5,4-c)pyridazine-3
A similar reaction and treatment using (2H)-one resulted in 2-(4-
chlorophenyl)-5,6-dihydro-[1]benzothiepino[5,4-c]pyridazine-3(2H)
-On is obtained. Example 13 10-chloro-2-(4-chlorophenyl)-5,6-dihydro-[1]benzothiepino[5,4-c]pyridazine-3(2H)- synthesized in Example 11
Add 300 ml of acetone and 25 ml of water to 2.4 g of onion, and add 2.8 g of sodium bromite trihydrate while stirring. After stirring at room temperature for 18 hours, it was concentrated under reduced pressure, water was added, and the precipitated crystals were collected by filtration and recrystallized from dimethylformamide-water. 4-chlorophenyl)-
5,6-dihydro-[1]benzothiepino[5,
4-c] 1.0 g of pyridazin-3(2H)-one 7-oxide is obtained. Example 14 Instead of 10-chloro-2-(4-chlorophenyl)-5,6-dihydro-[1]benzothiepino[5,4-c]pyridazin-3(2H)-one used in Example 13, 2-(4-chlorophenyl)-5,6-dihydro-[1]benzothiepino[5,4-c]pyridazine-3(2H)- synthesized in Example 12
2-(4-chlorophenyl)-5,6-dihydro-[1]benzothiepino[5,4-c]pyridazine- 3(2H)-
7-oxide is obtained. Example 15 Instead of 10-chloro-2-(4-chlorophenyl)-5,6-dihydro-[1]benzothiepino[5,4-c]pyridazin-3(2H)-one used in Example 13, By the same method using 2-(4-methoxyphenyl)-4,4a,5,6-tetrahydro[1]benzothiepino[5,4-c)pyridazin-3(2H)-one synthesized in Example 4 Upon reaction and treatment, 2-(4-methoxyphenyl)-4,4a, with a melting point of 203-205°C (decomposition),
5,6-tetrahydro[1]benzothiepino[5,4-c)pyridazin-3(2H)-one 7-
Oxide is obtained. Example 16 Instead of 10-chloro-2-(4-chlorophenyl)-5,6-dihydro-[1]benzothiepino[5,4-c]pyridazin-3(2H)-one used in Example 13, 2-phenyl-4,4a,5,6-tetrahydro[1]benzothiepino[5,4-c)pyridazine-3(2H)- synthesized in Example 1
When the reaction and treatment were carried out in a similar manner using (2H)
-one 7-oxide is obtained. Example 17 Instead of 10-chloro-2-(4-chlorophenyl)-5,6-dihydro-[1]benzothiepino[5,4-c]pyridazin-3(2H)-one used in Example 13, Using 2-(4-chlorophenyl)-4,4a,5,6-tetrahydro[1]benzothiepino[5,4-c)pyridazin-3(2H)-one synthesized in Example 3, reaction and reaction were performed in the same manner. When treated, melting point 217-220℃ (decomposition)
2-(4-chlorophenyl)-4,4a,5,6
-tetrahydro[1]benzothiepino[5,4-c)pyridazin-3(2H)-one 7-oxide is obtained. Example 18 2-(4-chlorophenyl) obtained in Example 17
-4,4a,5,6-tetrahydro[1]benzothiepino[5,4-c)pyridazine-3(2H)-
7-oxide was separated and purified by silica gel column chromatography using a mixed solvent of hexane-ethyl acetate (3:1) as the eluent,
When the crystals obtained from the first elution part are recrystallized from isopropyl alcohol, (4aR * ,7S * )-2-(4-chlorophenyl)-4,4a,5,6-tetrahydro has a melting point of 247-248℃ (decomposition). -[1]Benzothiepino[5,4-c)pyridazine-3
(2H)-one 7-oxide is obtained. Also,
When the crystals obtained from the second elution part are recrystallized from isopropyl alcohol, (4aR * ,7R * )-2-(4-chlorophenyl)-4,4a,5,6-tetrahydro, with a melting point of 190-191℃ (decomposition) [1] Benzothiepino[5,4-c)pyridazine-3(2H)
-one 7-oxide is obtained. Example 19 Instead of 10-chloro-2-(4-chlorophenyl)-5,6-dihydro-[1]benzothiepino[5,4-c]pyridazin-3(2H)-one used in Example 13, 10-chloro- synthesized in Example 10
2-(4-chlorophenyl)-4,4a,5,6-
A similar reaction and treatment using tetrahydro[1]benzothiepino[5,4-c)pyridazin-3(2H)-one results in a melting point of 198
10-chloro-2-(4-chlorophenyl)-4,4a,5,6-tetrahydro[1]benzothiepino[5,4-c)pyridazin-3(2H)-one 7-oxide at ~202°C (decomposition) is obtained. Example 20 2-(4-chlorophenyl) synthesized in Example 14
-5,6-dihydro-[1]benzothiepino[5,
4-c] Dissolve 14 g of pyridazin-3(2H)-one 7-oxide in 200 ml of acetic acid, and add 15 ml of hydrogen peroxide at room temperature while stirring. After further stirring for 2 hours at 50 to 55°C, the reaction solution was poured into 1 part of water, and the precipitated crystals were collected by filtration. The obtained crude product was purified by silica gel column chromatography and recrystallized from chloroform-methanol, resulting in a melting point of 310°C.
9.8 g of the above 2-(4-chlorophenyl)-5,6-dihydro-[1]benzothiepino[5,4-c]pyridazin-3(2H)-one 7,7-oxide
is obtained. Example 21 5-oxo 2,3,4,5 used in Example 1
-tetrahydro-[1]benzothiepine-4-acetic acid instead of 7-fluoro-5-oxo-2,
When the reaction and treatment are carried out in the same manner using 3,4,5-tetrahydro-[1]benzothiepine-4-acetic acid and 4-chlorophenylhydrazine instead of phenylhydrazine, the melting point is 141~ 2-(4-chlorophenyl) at 142℃
-10-Fluoro-4,4a,5,6-tetrahydro[1]benzothiepino[5,4-c)pyridazin-3(2H)-one is obtained. Example 22 Substitute for 10-chloro-2-(4-chlorophenyl)-4,4a,5,6-tetrahydro[1]benzothiepino[5,4-c)pyridazin-3(2H)-one used in Example 11 2-(4-chlorophenyl)-10-fluoro-4,4a,5,6-tetrahydro[1]benzothiepino[5,4-c)pyridazin-3(2H)-one was used to react and react in the same manner. With treatment, melting point 160-162℃
2-(4-chlorophenyl)-10-fluoro-
5,6-dihydro-[1]benzothiepino[5,
4-c]pyridazin-3(2H)-one is obtained. Example 23 2-(4-chlorophenyl) synthesized in Example 22
-10-Fluoro-5,6-dihydro-[1]benzothiepino[5,4-c]pyridazine-3(2H)
-1.8g dissolved in 20ml of acetic acid, stirred at room temperature, 35%
Add 1.3ml of hydrogen peroxide. Furthermore, at the same temperature 5
After stirring for an hour, water was added and the precipitated crystals were collected by filtration.
Dimethylformamide-2-(4-chlorophenyl)-10-fluoro-5,6-dihydro-[1]benzothiepino[5,4-c]pyridazine-3 with a melting point of 233-235°C (decomposition) when recrystallized from water.
1.3 g of (2H)-one 7-oxide are obtained. Example 24 9-chloro-5-oxo-2,3,4,5-tetrahydro-[1]benzothiepine-4-acetic acid 8 g
was dissolved in 100 ml of butanol, 5 g of 4-chlorophenylhydrazine was added, and the mixture was heated under reflux for 16 hours.
The solvent was distilled off, 20 ml of acetic acid was added to the residue, and the mixture was heated under reflux for 5 hours. After evaporating the solvent, water was added to the residue, and the mixture was extracted with ethyl acetate. After washing with an aqueous sodium hydrogen carbonate solution, drying over anhydrous magnesium sulfate, and distilling off the solvent. The residue was purified by silica gel column chromatography to obtain 3 g of a pale brown oil. Dissolve this in 30 ml of acetic acid and add 0.41 bromine at room temperature.
ml and further stirred for 1 hour at an internal temperature of 40-50°C. After the reaction, the solvent was distilled off under reduced pressure, and the residue was purified by silica gel column chromatography and recrystallized from ethanol, giving a melting point of 166-16.
8-chloro-2-(4-chlorophenyl)- at °C
5,6-dihydro-[1]benzothiepino[5,
4-c]pyridazin-3(2H)-one is obtained. Example 25 8-chloro-2-(4-chlorophenyl)-5,6-dihydro-[1]benzothiepino[5,4-c]pyridazine-3(2H)- synthesized in Example 24
Dissolve 0.9 g of ion in 20 ml of acetic acid and stir at room temperature.
Add 0.6ml of 35% hydrogen peroxide solution, and then at the same temperature.
Stir for 18 hours. By adding water, filtering out the precipitated crystals, and repeating the washing with ethanol, the melting point
8-chloro-2-(4-chlorophenyl)-5,6-dihydro-[1]benzothiepino[5,4-c]pyridazine-3(2H)- at 217-219°C (decomposition)
0.7 g of on.7-oxide is obtained. Example 26 4,4a,5,6-tetrahydro[1]benzothiepino[5,4-c)pyridazine-3(2H)-
Add 92g of bromine to 920ml of acetic acid and add 64g of bromine at 50-60℃
Drop it and keep at the same temperature for 1 hour. Pour in lots of water,
The resulting crystals are collected by filtration. After washing with brine and then ethanol and drying, -5,6-dihydro-[1]
Benzothiepino[5,4-c]pyridazine-3
Obtain 85 g of (2H)-one. Melting point 31-313°C (decomposition). Example 27 Dissolve 5 g of the compound obtained in Example 26 in 50 ml of dimethylformamide, add 1.0 g of sodium hydride at 60°C, and stir for 30 minutes. Methyl iodide at 35-40℃
Add 5g dropwise and keep at the same temperature for 1 hour. The reaction solution was poured into water, extracted with ethyl acetate, washed with water, and dried over magnesium sulfate. The crystals obtained by concentration are collected by filtration and recrystallized from ethanol to give 2-methyl-
5,6-dihydro-[1]benzothiepino[5,
4-c] 2.8 g of pyridazin-3(2H)-one are obtained.
Melting point 139-140℃. Example 28 When benzyl chloride is used in place of methyl iodide in Example 27, 2-benzyl-5,6-dihydro-[1]benzothiepino[5,4-c]pyridazin-3(2H)-one is obtained. It will be done. Melting point 190~
192℃. Example 29 Example 27 When 4-chlorobenzyl chloride is used in place of methyl iodide, 2-(4-chlorobenzyl)-5,6-dihydro-[1]benzothiepino[5,4-c]pyridazine-3 (2H)-one is obtained. Melting point 224-225℃. Example 30 When butyl bromide is used in place of methyl iodide in Example 27, 2-butyl-5,6-dihydro-[1]
Benzothiepino[5,4-c]pyridazine-3
(2H)-one is obtained. Melting point 108-110℃. Example 31 5.8g of the compound obtained in Example 28 was dissolved in 200ml of acetic acid,
Add 5 g of 35% hydrogen peroxide and keep at room temperature for 5 hours.
Pour into ice water, collect the formed crystals by filtration, and recrystallize from 60% acetic acid aqueous solution to obtain 2-(4-chlorobenzyl)-5,6-dihydro-[1]benzothiepino[5,4-c]pyridazine-3. (2H)-on・7-
4.2 g of oxide are obtained. Melting point 207-209°C (decomposition). Example 32 In addition to 3.4 g of the compound obtained in Example 31 and 200 ml of acetic acid,
Heat and dissolve at 45-50℃. 35% hydrogen peroxide solution
Add 20g and keep at the same temperature for 3 hours. Pour into a large amount of water, collect the resulting crystals by filtration, wash with water, and recrystallize from a 60% acetic acid aqueous solution to obtain 2-(4-chlorobenzyl)-5,6-dihydro-[1]benzothiepino[5,4- c] Pyridazine-3(2H)-one 7,
2.6 g of 7-oxide are obtained. Melting point 238-239°C (decomposition). The following compounds are obtained in the same manner as in the above examples. Example 33 2-(4-bromophenyl)-5,6-dihydro-[1]benzothiepino[5,4-c]pyridazin-3(2H)-one 7-oxide, melting point 227°C
(Disassembly). Example 34 10-Methyl-4,4a,5,6-tetrahydro[1]benzothiepino[5,4-c)pyridazin-3(2H)-one, melting point 185-187°C Example 35 2-(4-chlorophenyl) -10-methyl-4,
4a,5,6-tetrahydro[1]benzothiepino[5,4-c)pyridazin-3(2H)-one,
Melting point 151-153°C Example 36 10-methyl-2-(4-methylphenyl)-4,
4a,5,6-tetrahydro[1]benzothiepino[5,4-c)pyridazin-3(2H)-one,
Melting point 164-166°C Example 37 2-(4-bromophenyl)-4,4a,5,6
-tetrahydro[1]benzothiepino[5,4-c)pyridazin-3(2H)-one 7-oxide,
Melting point 227-229°C (decomposed) Example 38 2-(4-bromophenyl)-5,6-dihydro-[1]benzothiepino[5,4-c]pyridazin-3(2H)-one, melting point 199-201°C Example 39 2-(4-chlorophenyl)-10-methyl-5,
6-dihydro-[1]benzothiepino[5,4-
c] Pyridazin-3(2H)-one, melting point 182-184
°C Example 40 2-(4-chlorophenyl)-10-methyl-5,
6-dihydro-[1]benzothiepino[5,4-
c] pyridazin-3(2H)-one 7-oxide,
Melting point 237-239°C (decomposition) Example 41 10-fluoro-2-(4-fluorophenyl)-
4,4a,5,6-tetrahydro[1]benzothiepino[5,4-c)pyridazin-3(2H)-one, melting point 175-177°C Example 42 10-fluoro-2-(4-fluorophenyl)-
5,6-dihydro-[1]benzothiepino[5,
4-c] Pyridazin-3(2H)-one, melting point 169~
171℃ Example 43 10-fluoro-2-(4-fluorophenyl)-
5,6-dihydro-[1]benzothiepino[5,
4-c] Pyridazin-3(2H)-one 7-oxide, melting point 227-229°C (decomposition) Example 44 2-(4-fluorophenyl)-4,4a,5,
6-tetrahydro[1]benzothiepino[5,4
-c) Pyridazine-3(2H)-one, melting point 146~
147℃ Example 45 2-(4-fluorophenyl)-5,6-dihydro-[1]benzothiepino[5,4-c]pyridazin-3(2H)-one, melting point 163-165℃ Example 46 2 -(4-fluorophenyl)-5,6-dihydro-[1]benzothiepino[5,4-c]pyridazin-3(2H)-one 7-oxide, melting point 225~
226℃ (decomposition) Example 47 2-(3,4-dichlorophenyl)-4,4a,
5,6-tetrahydro[1]benzothiepino[5,4-c)pyridazin-3(2H)-one, melting point
134-136°C Example 48 10-Fluoro-2-(3,4-dichlorophenyl)-5,6-dihydro-[1]benzothiepino[5,4-c]pyridazin-3(2H)-one, melting point
156-157℃ Example 49 10-fluoro-2-(3-trifluoromethylphenyl)-5,6-dihydro-[1]benzothiepino[5,4-c]pyridazin-3(2H)-one 7 -oxide, melting point 203-204°C (decomposed) Example 50 10-fluoro-2-(3,4-dichlorophenyl)-5,6-dihydro-[1]benzothiepino[5,4-c]pyridazine-3 (2H)-on, 7,
7-dioxide, melting point 253-255°C (decomposition) Example 51 8-chloro-2-(4-chlorophenyl)-5,
6-dihydro-[1]benzothiepino[5,4-
c] Pyridazin-3(2H)-one 7,7-dioxide, melting point 219-220°C (decomposed) The present invention has been fully explained in the above specification and the examples contained therein; may be modified and modified in various ways without departing from the spirit and scope of the same.
Claims (1)
ハロゲン、トリフルオロメチル、ヒドロキシ、ア
ミノ、ニトロ、シアノ、C1-4アルキル、C1-4アル
コキシまたはC2-5アルカノイルアミノを、R3は
水素、C1-8アルキル、ヒドロキシ−C1-4アルキ
ル、C2-5アルカノイルオキシ−C1-4アルキル、ア
リール、アリールC1-4アルキル、ヘテロアリール
または芳香環上にハロゲン、トリフルオロメチ
ル、ヒドロキシ、アミノ、ニトロ、シアノ、C1-4
アルキル、C1-4アルコキシおよびC2-5アルカノイ
ルアミノから選ばれる置換基を1〜3個有するア
リール、アリール−C1-4アルキルもしくはヘテロ
アリールを、nは0,1または2を、4位と4a
位との間の結合―――………は単結合または二重結合を
示す。) で表わされるベンゾチエピノ〔5,4−c〕ピリ
ダジン化合物。[Claims] 1. General formula (In the formula, R 1 and R 2 are the same or different and hydrogen,
Halogen, trifluoromethyl, hydroxy, amino, nitro, cyano, C 1-4 alkyl, C 1-4 alkoxy or C 2-5 alkanoylamino, R 3 is hydrogen, C 1-8 alkyl, hydroxy-C 1- 4 alkyl, C 2-5 alkanoyloxy-C 1-4 alkyl, aryl, aryl C 1-4 alkyl, heteroaryl or halogen on aromatic ring, trifluoromethyl, hydroxy, amino, nitro, cyano, C 1-4
Aryl, aryl-C 1-4 alkyl or heteroaryl having 1 to 3 substituents selected from alkyl, C 1-4 alkoxy and C 2-5 alkanoylamino, n is 0, 1 or 2, 4-position and 4a
The bond between the two positions ----- indicates a single bond or a double bond. ) A benzothiepino[5,4-c]pyridazine compound represented by:
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP63048464A JPH01250383A (en) | 1987-03-02 | 1988-03-01 | Benzothiepino(5,4-c)pyridazine compound |
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP62-48497 | 1987-03-02 | ||
JP4849787 | 1987-03-02 | ||
JP62-172469 | 1987-07-09 | ||
JP62-306227 | 1987-12-02 | ||
JP63048464A JPH01250383A (en) | 1987-03-02 | 1988-03-01 | Benzothiepino(5,4-c)pyridazine compound |
Publications (2)
Publication Number | Publication Date |
---|---|
JPH01250383A JPH01250383A (en) | 1989-10-05 |
JPH0555509B2 true JPH0555509B2 (en) | 1993-08-17 |
Family
ID=26388741
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP63048464A Granted JPH01250383A (en) | 1987-03-02 | 1988-03-01 | Benzothiepino(5,4-c)pyridazine compound |
Country Status (1)
Country | Link |
---|---|
JP (1) | JPH01250383A (en) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5597918A (en) * | 1991-08-27 | 1997-01-28 | Yoshitomi Pharmaceutical Industries, Ltd. | Fused pyridazine compound |
CA2116448A1 (en) * | 1991-08-27 | 1993-03-04 | Tohru Nakao | Fused pyridazine compound and pharmaceutical use thereof |
-
1988
- 1988-03-01 JP JP63048464A patent/JPH01250383A/en active Granted
Also Published As
Publication number | Publication date |
---|---|
JPH01250383A (en) | 1989-10-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP6483697B2 (en) | Fused bicyclic heteroaromatic derivatives as modulators of TNF activity | |
DE69936998T2 (en) | PYRAZOLOTRIAZINE DERIVATIVES AS GABA RECEPTOR LIGANDS | |
US20040127492A1 (en) | Cyclic pyrazoles for the inhibition of mitogen activated protein kinase-activated protein kinase-2 | |
DE69637369T2 (en) | Tricyclic benzazepine vasopressin antagonists | |
JP3110765B2 (en) | Pyrid [2,3-d] pyrimidine derivatives and pharmaceutical compositions thereof | |
JP2001520227A (en) | Bicyclic kinase inhibitor | |
JP2002501066A (en) | Triazolo-pyridazine derivatives as ligands for GABA receptors | |
DE69630209T2 (en) | BICYCLIC BENZAZEPINE DERIVATIVES AS VASOPRESSIN ANTAGONISTS | |
WO1996022295A9 (en) | Tricyclic benzazepine vasopressin antagonists | |
JP2003516989A (en) | Pyrazolo-pyridine derivatives as GABA receptor ligands | |
US4613603A (en) | Compounds with a nitrogen-containing heterocyclic nucleus, and drugs in which they are present | |
US5514687A (en) | Benzopyrido piperidylidene compounds, compositions, methods of manufacture and method of use | |
JP2002507208A (en) | Tricyclic pyrazolo-pyridazinone analogs as GABA-A receptor ligands | |
JPH1179996A (en) | Quinazoline-4-one ampa antagonist | |
JPH0565288A (en) | New acylamino-substituted hetrazepine derivative, process for producing same and medicinal composition containing same | |
KR900006756B1 (en) | Benzothienpino (5,4-c) pyridazines and its pharmaceutical composition | |
US4965264A (en) | Thienocinnoline compounds and their pharmaceutical use | |
DE69907923T2 (en) | TRIAZOLOPYRIDAZINE DERIVATIVES FOR IMPROVING THE COGNITIVE FUNCTIONS | |
JPH0555509B2 (en) | ||
WO1990003380A1 (en) | Thienocycloheptapyridazine compounds and medicinal uses thereof | |
JP2969911B2 (en) | Thiophene compounds, their pharmaceutical uses and their synthetic intermediates | |
JP2002536449A (en) | Triazolo-pyridazine derivatives as ligands for GABA receptors | |
JP2615785B2 (en) | Thienocinnoline compounds | |
JPH06505698A (en) | new compound | |
JP2531687B2 (en) | Benzoxepino [5,4-c] pyridazine compounds |